Mustafa Khasraw
Professor of Neurosurgery
I am a medical oncologist, neuro-oncologist, tenured professor of medicine and neurooncology, and Deputy Director of the Center for Cancer Immunotherapy, Duke Cancer Institute, where we are tasked to speed up clinical research and translation for scientists across all departments and all tumor types at Duke, who have made discoveries that show promise for developing new immunotherapies.
I am leading clinical and translational programs with laboratory collaborations with an interest in innovative trials designed to improve the outcome of patients with cancers of the CNS.
I serve as an advisor and grant reviewer for several non-profits and patient advocacy groups. I am a Fellow of the Royal Australasian College of Physicians and an Elected Fellow of the Royal College of Physicians (UK).
Current Research Interests
My primary focus is to develop innovative trials using immune and targeted therapies and partner biomarkers, mainly in central nervous system tumors. Still, I have also published findings across multiple domains and in a diverse range of rare and underserved cancers such as neuroendocrine carcinomas and triple-negative breast cancer. My recent clinical trials are mainly focused on personalized immunotherapies that urgently need reliable and robust biomarkers. My research is at an interface between innovative clinical trials and translational research in the early phases of drug development.
Current Appointments & Affiliations
- Professor of Neurosurgery, Neurosurgery, Neurosurgery 2020
- Professor in Medicine, Medicine, Medical Oncology, Medicine 2020
- Member of the Duke Cancer Institute, Duke Cancer Institute, Institutes and Centers 2019
Contact Information
- Background
-
Education, Training, & Certifications
-
Previous Appointments & Affiliations
- Instructor in the Department of Neurosurgery, Neurosurgery, Neurosurgery 2019 - 2020
-
Leadership & Clinical Positions at Duke
-
Deputy Director of the Duke Center for Cancer Immunotherapy
Director of Translation and Developmental Therapeutics at the Duke Center for Brain and Spine Metastasis
-
-
Academic Positions Outside Duke
- Honorary Professor , University of Sydney. 2019 - 2040
- Recognition
-
In the News
-
MAR 4, 2021 NY Times
-
- Expertise
-
Subject Headings
- Research
-
Selected Grants
- A Multicenter, Open-Label Study with a Randomized Control Arm of the Efficacy, Safety, and Pharmacokinetics of Intravenously Infused Berubicin in Adult Patients with Recurrent Glioblastoma Multiform (WHO Grade IV) After Failure of Standard First Line awarded by CNS Pharmaceuticals, Inc 2022 - 2027
- Phase 1 BNT152+153 in patients with solid tumors awarded by BioNTech SE 2022 - 2027
- PARAMETer: A window of opportunity study of Patritumab Deruxtecan in patients with brain metastases awarded by Daiichi Sankyo Inc 2022 - 2026
- GBM AGILE Global Adaptive Trial Master Protocol: An International, Seamless Phase II/III Response Adaptive Randomization Platform Trial Designed To Evaluate Multiple Regimens In Newly Diagnosed and Recurrent GBM (GCAR-7213) awarded by Global Coalition 2021 - 2025
- Astellas 1951-CL-0101 awarded by Astellas Pharma Global Development, Inc 2020 - 2025
- Celldex CDX-527 awarded by Celldex Therapeutics, Inc. 2020 - 2025
- Prospective longitudinal sequencing of tumor and circulating DNA to assess response to radiation and other therapies in patients with glioblastoma awarded by Personalis, Inc. 2022 - 2024
- Clinical Brain Tumor Development of a Cytomegalovirus-targeted Therapeutic with Vaccine pre-conditioning to Validate Novel Predictors of Vaccine Efficacy awarded by National Institutes of Health 2018 - 2023
- NUTMEG Tissue Analysis awarded by University of Sydney 2022 - 2023
- Genomic and Epigenomic Blood sample Analysis for FIG Study awarded by Olivia Newton-John Cancer Research Institute 2021 - 2022
- T32 UNC - Duke Immunotherapy Training Program awarded by University of North Carolina - Chapel Hill 2021 - 2022
-
External Relationships
- Berg pharmaceuticals
- Bristol-Myers Squibb
- GSK
- George Clinical
- Janssen AI (Johnson & Johnson)
- Jax lab for genomic research
- Novocure Ltd
- Publications & Artistic Works
-
Selected Publications
-
Academic Articles
-
Omuro, Antonio, Alba A. Brandes, Antoine F. Carpentier, Ahmed Idbaih, David A. Reardon, Timothy Cloughesy, Ashley Sumrall, et al. “Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trial.” Neuro Oncol 25, no. 1 (January 5, 2023): 123–34. https://doi.org/10.1093/neuonc/noac099.Full Text Link to Item
-
Loi, Sherene, Christos S. Karapetis, Nicole McCarthy, Catherine Oakman, Andrew Redfern, Michelle White, Mustafa Khasraw, et al. “Palbociclib plus letrozole as treatment for postmenopausal women with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer for whom letrozole therapy is deemed appropriate: An expanded access study in Australia and India.” Asia Pac J Clin Oncol 18, no. 6 (December 2022): 560–69. https://doi.org/10.1111/ajco.13653.Full Text Link to Item
-
Yuile, Alexander, Mustafa Khasraw, Justin T. Low, Kyle M. Walsh, Eric Lipp, Joanne Sy, Laveniya Satgunaseelan, et al. “Patterns of care in adult histone mutant gliomas: Results of an international survey.” Neurooncol Pract 9, no. 6 (December 2022): 520–25. https://doi.org/10.1093/nop/npac047.Full Text Link to Item
-
Venugopal, Abhirami, Agnes Michalczyk, Mustafa Khasraw, and M Leigh Ackland. “EMT Molecular Signatures of Pancreatic Neuroendocrine Neoplasms.” Int J Mol Sci 23, no. 21 (November 7, 2022). https://doi.org/10.3390/ijms232113645.Full Text Link to Item
-
McGrail, D. J., P. G. Pilié, N. U. Rashid, L. Voorwerk, M. Slagter, M. Kok, E. Jonasch, et al. “Validation of cancer-type-dependent benefit from immune checkpoint blockade in TMB-H tumors identified by the FoundationOne CDx assay.” Ann Oncol 33, no. 11 (November 2022): 1204–6. https://doi.org/10.1016/j.annonc.2022.07.009.Full Text Link to Item
-
Tomaszewski, William H., Jessica Waibl-Polania, Molly Chakraborty, Jonathan Perera, Jeremy Ratiu, Alexandra Miggelbrink, Donald P. McDonnell, et al. “Neuronal CaMKK2 promotes immunosuppression and checkpoint blockade resistance in glioblastoma.” Nat Commun 13, no. 1 (October 29, 2022): 6483. https://doi.org/10.1038/s41467-022-34175-y.Full Text Link to Item
-
Varn, Frederick S., Kevin C. Johnson, Jan Martinek, Jason T. Huse, MacLean P. Nasrallah, Pieter Wesseling, Lee A. D. Cooper, et al. “Glioma progression is shaped by genetic evolution and microenvironment interactions.” Cell 185, no. 12 (June 9, 2022): 2184-2199.e16. https://doi.org/10.1016/j.cell.2022.04.038.Full Text Link to Item
-
Kong, Benjamin Y., Candace Carter, Anna K. Nowak, Elizabeth Hovey, Zarnie Lwin, Neda Haghighi, Hui K. Gan, et al. “Barriers and potential solutions to international collaboration in neuro-oncology clinical trials: Challenges from the Australian perspective.” Asia Pac J Clin Oncol 18, no. 3 (June 2022): 259–66. https://doi.org/10.1111/ajco.13606.Full Text Link to Item
-
Wei, Shiyou, Delong Yin, Shengnan Yu, Xiang Lin, Milan R. Savani, Kuang Du, Yin Ku, et al. “Antitumor Activity of a Mitochondrial-Targeted HSP90 Inhibitor in Gliomas.” Clin Cancer Res 28, no. 10 (May 13, 2022): 2180–95. https://doi.org/10.1158/1078-0432.CCR-21-0833.Full Text Link to Item
-
Low, Justin T., Vidyalakshmi Chandramohan, Michelle L. Bowie, Michael C. Brown, Matthew S. Waitkus, Aaron Briley, Kevin Stevenson, et al. “Epigenetic STING silencing is developmentally conserved in gliomas and can be rescued by methyltransferase inhibition.” Cancer Cell 40, no. 5 (May 9, 2022): 439–40. https://doi.org/10.1016/j.ccell.2022.04.009.Full Text Link to Item
-
Brown, Michael C., David M. Ashley, and Mustafa Khasraw. “Low tumor mutational burden and immunotherapy in gliomas.” Trends Cancer 8, no. 5 (May 2022): 345–46. https://doi.org/10.1016/j.trecan.2022.01.006.Full Text Link to Item
-
Sim, Hao-Wen, Evanthia Galanis, and Mustafa Khasraw. “PARP Inhibitors in Glioma: A Review of Therapeutic Opportunities.” Cancers (Basel) 14, no. 4 (February 16, 2022). https://doi.org/10.3390/cancers14041003.Full Text Link to Item
-
Bagley, Stephen J., Shawn Kothari, Rifaquat Rahman, Eudocia Q. Lee, Gavin P. Dunn, Evanthia Galanis, Susan M. Chang, et al. “Glioblastoma Clinical Trials: Current Landscape and Opportunities for Improvement.” Clin Cancer Res 28, no. 4 (February 15, 2022): 594–602. https://doi.org/10.1158/1078-0432.CCR-21-2750.Full Text Link to Item
-
Singh, Kirit, Kristen A. Batich, Patrick Y. Wen, Aaron C. Tan, Stephen J. Bagley, Michael Lim, Michael Platten, et al. “Designing Clinical Trials for Combination Immunotherapy: A Framework for Glioblastoma.” Clin Cancer Res 28, no. 4 (February 15, 2022): 585–93. https://doi.org/10.1158/1078-0432.CCR-21-2681.Full Text Link to Item
-
Brar, Karanbir, Shervin Taslimi, Yosef Ellenbogen, Jiawen Deng, Winston Hou, Fabio Y. Moraes, Michael Glantz, et al. “Comparative Efficacy of Treatments for Brain Metastases from Non-Small Cell Lung Cancer without an EGFR-Mutation/ALK-Rearrangement: A Systematic Review and Network Meta-Analysis.” World Neurosurgery 158 (February 2022): e87–102. https://doi.org/10.1016/j.wneu.2021.10.113.Full Text
-
Page, Alexander, Alex Broom, Katherine Kenny, Zarnie Lwin, Claire E. Wakefield, Malinda Itchins, and Mustafa Khasraw. “Experiencing the SARS-CoV-2 Pandemic Whilst Living With Cancer.” Qual Health Res 32, no. 3 (February 2022): 426–39. https://doi.org/10.1177/10497323211057082.Full Text Link to Item
-
Khasraw, Mustafa, Yoko Fujita, Catalina Lee-Chang, Irina V. Balyasnikova, Hinda Najem, and Amy B. Heimberger. “New Approaches to Glioblastoma.” Annu Rev Med 73 (January 27, 2022): 279–92. https://doi.org/10.1146/annurev-med-042420-102102.Full Text Link to Item
-
Groot, John F. de, Albert H. Kim, Sujit Prabhu, Ganesh Rao, Adrian W. Laxton, Peter E. Fecci, Barbara J. O’Brien, et al. “Efficacy of laser interstitial thermal therapy (LITT) for newly diagnosed and recurrent IDH wild-type glioblastoma.” Neurooncol Adv 4, no. 1 (2022): vdac040. https://doi.org/10.1093/noajnl/vdac040.Full Text Link to Item
-
Isaacs, James, Aaron C. Tan, Brent A. Hanks, Xiaofei Wang, Kouros Owzar, James E. Herndon, Scott J. Antonia, Steven Piantadosi, and Mustafa Khasraw. “Clinical Trials with Biologic Primary Endpoints in Immuno-oncology: Concepts and Usage.” Clin Cancer Res 28, no. 1 (January 1, 2022): 13–22. https://doi.org/10.1158/1078-0432.CCR-21-1593.Full Text Link to Item
-
Kong, B. Y., H. W. Sim, A. K. Nowak, S. Yip, E. H. Barnes, B. W. Day, M. E. Buckland, et al. “LUMOS - Low and Intermediate Grade Glioma Umbrella Study of Molecular Guided TherapieS at relapse: Protocol for a pilot study.” Bmj Open 11, no. 12 (December 30, 2021). https://doi.org/10.1136/bmjopen-2021-054075.Full Text
-
Yu, Shengnan, Shiyou Wei, Milan Savani, Xiang Lin, Kuang Du, Ilgen Mender, Silvia Siteni, et al. “A Modified Nucleoside 6-Thio-2'-Deoxyguanosine Exhibits Antitumor Activity in Gliomas.” Clin Cancer Res 27, no. 24 (December 15, 2021): 6800–6814. https://doi.org/10.1158/1078-0432.CCR-21-0374.Full Text Link to Item
-
Kenny, Katherine, Alex Broom, Alexander Page, Barbara Prainsack, Claire E. Wakefield, Malinda Itchins, Zarnie Lwin, and Mustafa Khasraw. “A sociology of precision-in-practice: The affective and temporal complexities of everyday clinical care.” Sociol Health Illn 43, no. 9 (November 2021): 2178–95. https://doi.org/10.1111/1467-9566.13389.Full Text Link to Item
-
Singh, Kirit, Kelly M. Hotchkiss, Aditya A. Mohan, Jessica L. Reedy, John H. Sampson, and Mustafa Khasraw. “For whom the T cells troll? Bispecific T-cell engagers in glioblastoma.” J Immunother Cancer 9, no. 11 (November 2021). https://doi.org/10.1136/jitc-2021-003679.Full Text Link to Item
-
Srinivasan, Ethan S., Krutika Deshpande, Josh Neman, Frank Winkler, and Mustafa Khasraw. “The microenvironment of brain metastases from solid tumors.” Neurooncol Adv 3, no. Suppl 5 (November 2021): v121–32. https://doi.org/10.1093/noajnl/vdab121.Full Text Link to Item
-
Rahman, Rifaquat, Steffen Ventz, Jon McDunn, Bill Louv, Irmarie Reyes-Rivera, Mei-Yin C. Polley, Fahar Merchant, et al. “Leveraging external data in the design and analysis of clinical trials in neuro-oncology.” Lancet Oncol 22, no. 10 (October 2021): e456–65. https://doi.org/10.1016/S1470-2045(21)00488-5.Full Text Link to Item
-
McGrail, D. J., P. G. Pilié, N. U. Rashid, L. Voorwerk, M. Slagter, M. Kok, E. Jonasch, et al. “Reply to: 'Real-world prevalence across 159 872 patients with cancer supports the clinical utility of TMB-H to define metastatic solid tumors for treatment with pembrolizumab.' by D. Fabrizio et al.” Ann Oncol 32, no. 9 (September 2021): 1194–97. https://doi.org/10.1016/j.annonc.2021.06.017.Full Text Link to Item
-
Najem, Hinda, Mustafa Khasraw, and Amy B. Heimberger. “Immune Microenvironment Landscape in CNS Tumors and Role in Responses to Immunotherapy.” Cells 10, no. 8 (August 9, 2021). https://doi.org/10.3390/cells10082032.Full Text Link to Item
-
Lee, Eudocia Q., Wendy Selig, Clair Meehan, Jeffrey Bacha, Amy Barone, Erik Bloomquist, Susan M. Chang, et al. “Report of National Brain Tumor Society roundtable workshop on innovating brain tumor clinical trials: building on lessons learned from COVID-19 experience.” Neuro Oncol 23, no. 8 (August 2, 2021): 1252–60. https://doi.org/10.1093/neuonc/noab082.Full Text Link to Item
-
Sim, Hao-Wen, Anna K. Nowak, Zarnie Lwin, and Mustafa Khasraw. “Management of glioblastoma: an Australian perspective.” Chin Clin Oncol 10, no. 4 (August 2021): 42. https://doi.org/10.21037/cco.2020.02.05.Full Text Link to Item
-
Tan, Aaron C., Stephen J. Bagley, Patrick Y. Wen, Michael Lim, Michael Platten, Howard Colman, David M. Ashley, et al. “Systematic review of combinations of targeted or immunotherapy in advanced solid tumors.” J Immunother Cancer 9, no. 7 (July 2021). https://doi.org/10.1136/jitc-2021-002459.Full Text Link to Item
-
McGrail, D. J., P. G. Pilié, N. U. Rashid, L. Voorwerk, M. Slagter, M. Kok, E. Jonasch, et al. “High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types.” Ann Oncol 32, no. 5 (May 2021): 661–72. https://doi.org/10.1016/j.annonc.2021.02.006.Full Text Link to Item
-
Tan, Aaron C., Johan Chan, and Mustafa Khasraw. “The role of immunotherapy in fusion-driven lung cancer.” Expert Rev Anticancer Ther 21, no. 5 (May 2021): 461–64. https://doi.org/10.1080/14737140.2021.1899816.Full Text Link to Item
-
Venugopal, Abhirami, Jessie Gillick-Walker, Agnes Michalczyk, Mustafa Khasraw, and M Leigh Ackland. “mRNA profiling of a well-differentiated G1 pancreatic NET correlates with immunohistochemistry profile: a case report.” Bmc Gastroenterol 21, no. 1 (April 27, 2021): 194. https://doi.org/10.1186/s12876-021-01705-9.Full Text Link to Item
-
Taylor, Amelia M., David Lok Hang Chan, Martin Tio, Sujata M. Patil, Tiffany A. Traina, Mark E. Robson, and Mustafa Khasraw. “PARP (Poly ADP-Ribose Polymerase) inhibitors for locally advanced or metastatic breast cancer.” Cochrane Database Syst Rev 4, no. 4 (April 22, 2021): CD011395. https://doi.org/10.1002/14651858.CD011395.pub2.Full Text Link to Item
-
Srinivasan, Ethan S., Aaron C. Tan, Carey K. Anders, Ann Marie Pendergast, Dorothy A. Sipkins, David M. Ashley, Peter E. Fecci, and Mustafa Khasraw. “Salting the Soil: Targeting the Microenvironment of Brain Metastases.” Mol Cancer Ther 20, no. 3 (March 2021): 455–66. https://doi.org/10.1158/1535-7163.MCT-20-0579.Full Text Link to Item
-
Strickler, John H., Brent A. Hanks, and Mustafa Khasraw. “Tumor Mutational Burden as a Predictor of Immunotherapy Response: Is More Always Better?” Clin Cancer Res 27, no. 5 (March 1, 2021): 1236–41. https://doi.org/10.1158/1078-0432.CCR-20-3054.Full Text Link to Item
-
Luke, Jason J., Fabrice Barlesi, Ki Chung, Anthony W. Tolcher, Karen Kelly, Antoine Hollebecque, Christophe Le Tourneau, et al. “Phase I study of ABBV-428, a mesothelin-CD40 bispecific, in patients with advanced solid tumors.” J Immunother Cancer 9, no. 2 (February 2021). https://doi.org/10.1136/jitc-2020-002015.Full Text Link to Item
-
Gromeier, Matthias, Michael C. Brown, Gao Zhang, Xiang Lin, Yeqing Chen, Zhi Wei, Nike Beaubier, et al. “Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapy.” Nat Commun 12, no. 1 (January 13, 2021): 352. https://doi.org/10.1038/s41467-020-20469-6.Full Text Open Access Copy Link to Item
-
Ferguson, Sherise D., Tiffany R. Hodges, Nazanin K. Majd, Kristin Alfaro-Munoz, Wajd N. Al-Holou, Dima Suki, John F. de Groot, et al. “A validated integrated clinical and molecular glioblastoma long-term survival-predictive nomogram.” Neurooncol Adv 3, no. 1 (2021): vdaa146. https://doi.org/10.1093/noajnl/vdaa146.Full Text Link to Item
-
Khasraw, Mustafa, Michael Weller, David Lorente, Kathryn Kolibaba, Chee Khoon Lee, Craig Gedye, Macarena I de La Fuente, et al. “Bintrafusp alfa (M7824), a bifunctional fusion protein targeting TGF-β and PD-L1: results from a phase I expansion cohort in patients with recurrent glioblastoma.” Neurooncol Adv 3, no. 1 (2021): vdab058. https://doi.org/10.1093/noajnl/vdab058.Full Text Link to Item
-
Mohan, Aditya A., William H. Tomaszewski, Aden P. Haskell-Mendoza, Kelly M. Hotchkiss, Kirit Singh, Jessica L. Reedy, Peter E. Fecci, John H. Sampson, and Mustafa Khasraw. “Targeting Immunometabolism in Glioblastoma.” Front Oncol 11 (2021): 696402. https://doi.org/10.3389/fonc.2021.696402.Full Text Link to Item
-
Soffietti, R., M. Khasraw, J. Huse, and M. Hegi. “Highlights from the Literature.” Neuro Oncology 23, no. 1 (January 1, 2021): 14–16. https://doi.org/10.1093/neuonc/noaa271.Full Text
-
Tan, Aaron C., Drexell H. Boggs, Eudocia Q. Lee, Michelle M. Kim, Minesh P. Mehta, and Mustafa Khasraw. “Clinical Trial Eligibility Criteria and Recently Approved Cancer Therapies for Patients With Brain Metastases.” Front Oncol 11 (2021): 780379. https://doi.org/10.3389/fonc.2021.780379.Full Text Link to Item
-
Taslimi, Shervin, Karanbir Brar, Yosef Ellenbogen, Jiawen Deng, Winston Hou, Fabio Y. Moraes, Michael Glantz, et al. “Comparative Efficacy of Systemic Agents for Brain Metastases From Non-Small-Cell Lung Cancer With an EGFR Mutation/ALK Rearrangement: A Systematic Review and Network Meta-Analysis.” Front Oncol 11 (2021): 739765. https://doi.org/10.3389/fonc.2021.739765.Full Text Link to Item
-
Khasraw, Mustafa, Kyle M. Walsh, Amy B. Heimberger, and David M. Ashley. “What is the Burden of Proof for Tumor Mutational Burden in gliomas?” Neuro Oncol 23, no. 1 (November 30, 2020): 17–22. https://doi.org/10.1093/neuonc/noaa256.Full Text Link to Item
-
Broom, Alex, Katherine Kenny, Alexander Page, Nicole Cort, Eric S. Lipp, Aaron C. Tan, David M. Ashley, Kyle M. Walsh, and Mustafa Khasraw. “The Paradoxical Effects of COVID-19 on Cancer Care: Current Context and Potential Lasting Impacts.” Clin Cancer Res 26, no. 22 (November 15, 2020): 5809–13. https://doi.org/10.1158/1078-0432.CCR-20-2989.Full Text Link to Item
-
Khasraw, Mustafa, David A. Reardon, Michael Weller, and John H. Sampson. “PD-1 Inhibitors: Do they have a Future in the Treatment of Glioblastoma?” Clin Cancer Res 26, no. 20 (October 15, 2020): 5287–96. https://doi.org/10.1158/1078-0432.CCR-20-1135.Full Text Link to Item
-
Tan, Aaron C., David M. Ashley, Giselle Y. López, Michael Malinzak, Henry S. Friedman, and Mustafa Khasraw. “Management of glioblastoma: State of the art and future directions.” Ca Cancer J Clin 70, no. 4 (July 2020): 299–312. https://doi.org/10.3322/caac.21613.Full Text Link to Item
-
Tan, Aaron C., David M. Ashley, and Mustafa Khasraw. “Adapting to a Pandemic - Conducting Oncology Trials during the SARS-CoV-2 Pandemic.” Clin Cancer Res 26, no. 13 (July 1, 2020): 3100–3103. https://doi.org/10.1158/1078-0432.CCR-20-1364.Full Text Link to Item
-
Holloway-Kew, Kara L., Tim R. Baker, Muhammad A. Sajjad, Mark A. Kotowicz, Patricia M. Livingston, Mustafa Khasraw, Sharon Hakkennes, et al. “WITHDRAWN: The epidemiology of emergency presentations for falls across Western Victoria, Australia.” Australas Emerg Care, June 27, 2020. https://doi.org/10.1016/j.auec.2020.06.003.Full Text Link to Item
-
Holloway-Kew, Kara L., Tim R. Baker, Muhammad A. Sajjad, Mark A. Kotowicz, Patricia M. Livingston, Mustafa Khasraw, Sharon Hakkennes, et al. “The epidemiology of emergency presentations for falls from height across Western Victoria, Australia.” Australas Emerg Care 23, no. 2 (June 2020): 119–25. https://doi.org/10.1016/j.auec.2019.09.002.Full Text Link to Item
-
Lee, Adrian, Malmaruha Arasaratnam, David Lok Hang Chan, Mustafa Khasraw, Viive M. Howell, and Helen Wheeler. “Anti-epidermal growth factor receptor therapy for glioblastoma in adults.” Cochrane Database Syst Rev 5, no. 5 (May 12, 2020): CD013238. https://doi.org/10.1002/14651858.CD013238.pub2.Full Text Link to Item
-
Chan, Joseph, Dasantha Jayamanne, Helen Wheeler, Mustafa Khasraw, Matthew Wong, Marina Kastelan, Lesley Guo, and Michael Back. “The role of large volume re-irradiation with Bevacizumab in chemorefractory high grade glioma.” Clin Transl Radiat Oncol 22 (May 2020): 33–39. https://doi.org/10.1016/j.ctro.2020.03.005.Full Text Link to Item
-
Tan, Aaron C., Malinda Itchins, and Mustafa Khasraw. “Brain Metastases in Lung Cancers with Emerging Targetable Fusion Drivers.” Int J Mol Sci 21, no. 4 (February 19, 2020). https://doi.org/10.3390/ijms21041416.Full Text Link to Item
-
Anderson, Kevin J., Aaron C. Tan, Jonathon Parkinson, Michael Back, Marina Kastelan, Allison Newey, Janice Brewer, et al. “Molecular and clonal evolution in recurrent metastatic gliosarcoma.” Cold Spring Harb Mol Case Stud 6, no. 1 (February 2020). https://doi.org/10.1101/mcs.a004671.Full Text Link to Item
-
Gedye, C., M. Sachchithananthan, R. Leonard, R. L. Jeffree, M. E. Buckland, D. S. Ziegler, M. B. Graeber, et al. “Driving innovation through collaboration: Development of clinical annotation datasets for brain cancer biobanking.” Neuro Oncology Practice 7, no. 1 (January 31, 2020): 31–37. https://doi.org/10.1093/nop/npz036.Full Text
-
Charest, A., J. Huse, M. Khasraw, and M. Viapiano. “Highlights from the Literature.” Neuro Oncology 22, no. 1 (January 1, 2020): 13. https://doi.org/10.1093/NEUONC/NOZ221.Full Text
-
Back, M., D. Jayamanne, D. Brazier, A. Newey, D. Bailey, G. Schembri, E. Hsiao, et al. “Pattern of failure in anaplastic glioma patients with an IDH1/2 mutation.” Strahlenther Onkol 196, no. 1 (January 2020): 31–39. https://doi.org/10.1007/s00066-019-01467-0.Full Text Link to Item
-
Guccione, Lisa, Karla Gough, Allison Drosdowsky, Krista Fisher, Timothy Price, Nick Pavlakis, Mustafa Khasraw, et al. “Defining the Supportive Care Needs and Psychological Morbidity of Patients With Functioning Versus Nonfunctioning Neuroendocrine Tumors: Protocol for a Phase 1 Trial of a Nurse-Led Online and Phone-Based Intervention.” Jmir Res Protoc 8, no. 12 (December 3, 2019): e14361. https://doi.org/10.2196/14361.Full Text Link to Item
-
Holloway-Kew, Kara L., Tim R. Baker, Muhammad A. Sajjad, Mark A. Kotowicz, Patricia M. Livingston, Mustafa Khasraw, Sharon Hakkennes, et al. “The epidemiology of emergency presentations for falls across Western Victoria, Australia.” Australas Emerg Care 22, no. 4 (December 2019): 206–15. https://doi.org/10.1016/j.auec.2019.08.003.Full Text Link to Item
-
Barthel, Floris P., Kevin C. Johnson, Frederick S. Varn, Anzhela D. Moskalik, Georgette Tanner, Emre Kocakavuk, Kevin J. Anderson, et al. “Longitudinal molecular trajectories of diffuse glioma in adults.” Nature 576, no. 7785 (December 2019): 112–20. https://doi.org/10.1038/s41586-019-1775-1.Full Text Link to Item
-
Ghasemi, David R., Martin Sill, Konstantin Okonechnikov, Andrey Korshunov, Stephen Yip, Peter W. Schutz, David Scheie, et al. “MYCN amplification drives an aggressive form of spinal ependymoma.” Acta Neuropathol 138, no. 6 (December 2019): 1075–89. https://doi.org/10.1007/s00401-019-02056-2.Full Text Link to Item
-
Back, Michael F., Dasantha Jayamanne, Elizabeth Back, Marina Kastelan, Mustafa Khasraw, Matthew Wong, Christopher Brown, and Helen Wheeler. “Reflecting on survivorship outcomes to aid initial decision making in patients treated for IDH-mutated anaplastic glioma.” Cancer 125, no. 19 (October 1, 2019): 3457–66. https://doi.org/10.1002/cncr.32352.Full Text Link to Item
-
Cowdery, Stephanie P., Muhammad A. Sajjad, Kara L. Holloway-Kew, Mohammadreza Mohebbi, Lana J. Williams, Mark A. Kotowicz, Patricia M. Livingston, et al. “Mapping Cancer incidence across Western Victoria: the association with age, accessibility, and socioeconomic status among men and women.” Bmc Cancer 19, no. 1 (September 6, 2019): 892. https://doi.org/10.1186/s12885-019-6070-x.Full Text Link to Item
-
Heng, Sharon, Brett Hughes, Michael Hibbert, Mustafa Khasraw, and Zarnie Lwin. “Traveling With Cancer: A Guide for Oncologists in the Modern World.” J Glob Oncol 5 (July 2019): 1–10. https://doi.org/10.1200/JGO.19.00029.Full Text Link to Item
-
Brennan-Olsen, Sharon L., Sara Vogrin, Stephen Graves, Kara L. Holloway-Kew, Richard S. Page, M Amber Sajjad, Mark A. Kotowicz, et al. “Revision joint replacement surgeries of the hip and knee across geographic region and socioeconomic status in the western region of Victoria: a cross-sectional multilevel analysis of registry data.” Bmc Musculoskelet Disord 20, no. 1 (June 25, 2019): 300. https://doi.org/10.1186/s12891-019-2676-z.Full Text Link to Item
-
Sajjad, Muhammad A., Kara L. Holloway-Kew, Mohammadreza Mohebbi, Mark A. Kotowicz, Lelia L. F. de Abreu, Patricia M. Livingston, Mustafa Khasraw, et al. “Association between area-level socioeconomic status, accessibility and diabetes-related hospitalisations: a cross-sectional analysis of data from Western Victoria, Australia.” Bmj Open 9, no. 5 (May 22, 2019): e026880. https://doi.org/10.1136/bmjopen-2018-026880.Full Text Link to Item
-
Chang, Susan M., Hans Messersmith, Manmeet Ahluwalia, David Andrews, Priscilla K. Brastianos, Laurie E. Gaspar, Na Tosha N. Gatson, et al. “Anticonvulsant Prophylaxis and Steroid Use in Adults With Metastatic Brain Tumors: ASCO and SNO Endorsement of the Congress of Neurological Surgeons Guidelines.” J Clin Oncol 37, no. 13 (May 1, 2019): 1130–35. https://doi.org/10.1200/JCO.18.02085.Full Text Link to Item
-
Back, Michael, Dasantha T. Jayamanne, David Brazier, Alison Newey, Dale Bailey, Geoffrey P. Schembri, Edward Hsiao, et al. “Influence of molecular classification in anaplastic glioma for determining outcome and future approach to management.” J Med Imaging Radiat Oncol 63, no. 2 (April 2019): 272–80. https://doi.org/10.1111/1754-9485.12850.Full Text Link to Item
-
Chang, Susan M., Hans Messersmith, Manmeet Ahluwalia, David Andrews, Priscilla K. Brastianos, Laurie E. Gaspar, Na Tosha N. Gatson, et al. “Anticonvulsant prophylaxis and steroid use in adults with metastatic brain tumors: summary of SNO and ASCO endorsement of the Congress of Neurological Surgeons guidelines.” Neuro Oncol 21, no. 4 (March 18, 2019): 424–27. https://doi.org/10.1093/neuonc/noz034.Full Text Link to Item
-
Ha, Wendy, Hatice Sevim-Nalkiran, Ashraf M. Zaman, Kazuko Matsuda, Mustafa Khasraw, Anna K. Nowak, Liping Chung, Robert C. Baxter, and Kerrie L. McDonald. “Ibudilast sensitizes glioblastoma to temozolomide by targeting Macrophage Migration Inhibitory Factor (MIF).” Sci Rep 9, no. 1 (February 27, 2019): 2905. https://doi.org/10.1038/s41598-019-39427-4.Full Text Link to Item
-
Lee, Adrian, Malmaruha Arasaratnam, David Lok Hang Chan, Mustafa Khasraw, Viive M. Howell, Helen Wheeler, and Joanne Platt. “Anti‐epidermal growth factor receptor therapy for glioblastoma in adults.” The Cochrane Database of Systematic Reviews 2019, no. 1 (January 2019).
-
Murphy, Caitlin, Andrea Muscat, David Ashley, Violet Mukaro, Linda West, Yang Liao, David Chisanga, et al. “Tailored NEOadjuvant epirubicin, cyclophosphamide and Nanoparticle Albumin-Bound paclitaxel for breast cancer: The phase II NEONAB trial-Clinical outcomes and molecular determinants of response.” Plos One 14, no. 2 (2019): e0210891. https://doi.org/10.1371/journal.pone.0210891.Full Text Link to Item
-
Shapiro, Jeremy D., Subotheni Thavaneswaran, Craig R. Underhill, Kristy P. Robledo, Christos S. Karapetis, Fiona L. Day, Louise M. Nott, et al. “Cetuximab Alone or With Irinotecan for Resistant KRAS-, NRAS-, BRAF- and PIK3CA-wild-type Metastatic Colorectal Cancer: The AGITG Randomized Phase II ICECREAM Study.” Clin Colorectal Cancer 17, no. 4 (December 2018): 313–19. https://doi.org/10.1016/j.clcc.2018.06.002.Full Text Link to Item
-
Ferguson, Sherise D., Siyuan Zheng, Joanne Xiu, Shouhao Zhou, Mustafa Khasraw, Priscilla K. Brastianos, Santosh Kesari, et al. “Profiles of brain metastases: Prioritization of therapeutic targets.” Int J Cancer 143, no. 11 (December 1, 2018): 3019–26. https://doi.org/10.1002/ijc.31624.Full Text Link to Item
-
Ameratunga, Malaka, Nick Pavlakis, Helen Wheeler, Robin Grant, John Simes, and Mustafa Khasraw. “Anti-angiogenic therapy for high-grade glioma.” Cochrane Database Syst Rev 11, no. 11 (November 22, 2018): CD008218. https://doi.org/10.1002/14651858.CD008218.pub4.Full Text Link to Item
-
Ameratunga, Malaka, Nick Pavlakis, Helen Wheeler, Robin Grant, John Simes, and Mustafa Khasraw. “EPID-13. ANTI-ANGIOGENIC THERAPY FOR HIGH-GRADE GLIOMA: A META-ANALYSIS.” Neuro Oncology 20, no. Suppl 6 (November 2018): vi82–83.
-
Khasraw, Mustafa, Kerrie McDonald, Sonia Yip, Roel Verhaak, Amy Heimberger, Merryn Hall, Lauren Fisher, et al. “RBTT-07. NUTMEG: A RANDOMISED PHASE II STUDY OF NIVOLUMAB AND TEMOZOLOMIDE (TMZ) VS TMZ ALONE IN ELDERLY PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM): TRIAL IN PROGRESS.” Neuro Oncology 20, no. Suppl 6 (November 2018): vi235–vi235.
-
Khasraw, Mustafa, Michael Weller, David Lorente Estelles, Kathryn Kolibaba, Chee Lee, Craig Gedye, Macarena De La Fuente, et al. “ATIM-16. PHASE 1 STUDY RESULTS OF M7824 (MSB0011359C), A BIFUNCTIONAL FUSION PROTEIN TARGETING TGF- AND PD-L1, AMONG PATIENTS WITH RECURRENT GLIOBLASTOMA (rGBM).” Neuro Oncology 20, no. Suppl 6 (November 2018): vi4–vi4.
-
Back, Michael, Dasantha Jayamanne, Nicola Cove, Helen Wheeler, Mustafa Khasraw, Linxin Guo, Jemimah Back, and Matthew Wong. “Optimising Outcomes for Glioblastoma through Subspecialisation in a Regional Cancer Centre.” Brain Sci 8, no. 10 (October 15, 2018). https://doi.org/10.3390/brainsci8100186.Full Text Link to Item
-
Back, M., M. Rodriguez, D. Jayamanne, M. Khasraw, A. Lee, and H. Wheeler. “Understanding the Revised Fourth Edition of the World Health Organization Classification of Tumours of the Central Nervous System (2016) for Clinical Decision-making: A Guide for Oncologists Managing Patients with Glioma.” Clin Oncol (R Coll Radiol) 30, no. 9 (September 2018): 556–62. https://doi.org/10.1016/j.clon.2018.06.005.Full Text Link to Item
-
Khasraw, M., K. McDonald, S. Yip, R. G. Verhaak, A. B. Heimberger, M. Hall, E. Barnes, E. Hovey, B. M. Ellingson, and Z. Lwin. “P01.035 Nivolumab and Temozolomide (TMZ) vs TMZ alone in newly diagnosed elderly patients (pts) with Glioblastoma (GBM) (NUTMEG): Trial in progress.” Neuro Oncology 20, no. Suppl 3 (September 2018): iii236–iii236.
-
Brennan-Olsen, Sharon, Sara Vogrin, Kara L. Holloway, Richard S. Page, Muhammad A. Sajjad, Mark A. Kotowicz, Patricia M. Livingston, et al. “Correction to: Geographic region, socioeconomic position and the utilisation of primary total joint replacement for hip or knee osteoarthritis across western Victoria: a cross-sectional multilevel study of the Australian Orthopaedic Association National Joint Replacement Registry.” Arch Osteoporos 13, no. 1 (July 9, 2018): 75. https://doi.org/10.1007/s11657-018-0484-y.Full Text Link to Item
-
GLASS Consortium, Suresh. “Glioma through the looking GLASS: molecular evolution of diffuse gliomas and the Glioma Longitudinal Analysis Consortium.” Neuro Oncol 20, no. 7 (June 18, 2018): 873–84. https://doi.org/10.1093/neuonc/noy020.Full Text Link to Item
-
Leyden, John, Nick Pavlakis, David Chan, Michael Michael, Stephen Clarke, Mustafa Khasraw, and Timothy Price. “Patient-reported experience of the impact and burden of neuroendocrine tumors: Oceania patient results from a large global survey.” Asia Pac J Clin Oncol 14, no. 3 (June 2018): 256–63. https://doi.org/10.1111/ajco.12785.Full Text Link to Item
-
Murphy, Caitlin, Violet Mukaro, Robert Tobler, Rebecca Asher, Emma Gibbs, Linda West, Bruno Giuffre, Sally Baron-Hay, and Mustafa Khasraw. “Evaluating the role of magnetic resonance imaging post-neoadjuvant therapy for breast cancer in the NEONAB trial.” Intern Med J 48, no. 6 (June 2018): 699–705. https://doi.org/10.1111/imj.13617.Full Text Link to Item
-
Wann, Alysson, Patrick A. Tully, Elizabeth H. Barnes, Zarnie Lwin, Rosalind Jeffree, Katharine J. Drummond, Hui Gan, and Mustafa Khasraw. “Outcomes after second surgery for recurrent glioblastoma: a retrospective case-control study.” J Neurooncol 137, no. 2 (April 2018): 409–15. https://doi.org/10.1007/s11060-017-2731-2.Full Text Link to Item
-
Holloway, Kara L., Muhammad A. Sajjad, Mohammadreza Mohebbi, Mark A. Kotowicz, Patricia M. Livingston, Mustafa Khasraw, Sharon Hakkennes, et al. “The epidemiology of hip fractures across western Victoria, Australia.” Bone 108 (March 2018): 1–9. https://doi.org/10.1016/j.bone.2017.12.007.Full Text Link to Item
-
Alexander, Brian M., Sujuan Ba, Mitchel S. Berger, Donald A. Berry, Webster K. Cavenee, Susan M. Chang, Timothy F. Cloughesy, et al. “Adaptive Global Innovative Learning Environment for Glioblastoma: GBM AGILE.” Clin Cancer Res 24, no. 4 (February 15, 2018): 737–43. https://doi.org/10.1158/1078-0432.CCR-17-0764.Full Text Link to Item
-
Muscat, Andrea M., Nicholas C. Wong, Katharine J. Drummond, Elizabeth M. Algar, Mustafa Khasraw, Roel Verhaak, Kathryn Field, Mark A. Rosenthal, and David M. Ashley. “The evolutionary pattern of mutations in glioblastoma reveals therapy-mediated selection.” Oncotarget 9, no. 8 (January 30, 2018): 7844–58. https://doi.org/10.18632/oncotarget.23541.Full Text Link to Item
-
Hayes, Aimee R., Dasantha Jayamanne, Edward Hsiao, Geoffrey P. Schembri, Dale L. Bailey, Paul J. Roach, Mustafa Khasraw, Allison Newey, Helen R. Wheeler, and Michael Back. “Utilizing 18F-fluoroethyltyrosine (FET) positron emission tomography (PET) to define suspected nonenhancing tumor for radiation therapy planning of glioblastoma.” Pract Radiat Oncol 8, no. 4 (2018): 230–38. https://doi.org/10.1016/j.prro.2018.01.006.Full Text Link to Item
-
Raymond, Eric, Matthew H. Kulke, Shukui Qin, Xianjun Yu, Michael Schenker, Antonio Cubillo, Wenhui Lou, et al. “Efficacy and Safety of Sunitinib in Patients with Well-Differentiated Pancreatic Neuroendocrine Tumours.” Neuroendocrinology 107, no. 3 (2018): 237–45. https://doi.org/10.1159/000491999.Full Text Link to Item
-
Brennan-Olsen, Sharon, Sara Vogrin, Kara L. Holloway, Richard S. Page, Muhammad A. Sajjad, Mark A. Kotowicz, Patricia M. Livingston, et al. “Geographic region, socioeconomic position and the utilisation of primary total joint replacement for hip or knee osteoarthritis across western Victoria: a cross-sectional multilevel study of the Australian Orthopaedic Association National Joint Replacement Registry.” Arch Osteoporos 12, no. 1 (November 6, 2017): 97. https://doi.org/10.1007/s11657-017-0396-2.Full Text Link to Item
-
Phillips, Claire, Rosalind Jeffree, and Mustafa Khasraw. “Reply to Dr Altundag from the authors of 'Management of breast cancer brain metastases; a practical review'.” Breast 34 (August 2017): 133. https://doi.org/10.1016/j.breast.2016.11.026.Full Text Link to Item
-
Harris, Georgia, Dasantha Jayamanne, Helen Wheeler, Cecelia Gzell, Marina Kastelan, Geoff Schembri, David Brazier, et al. “Survival Outcomes of Elderly Patients With Glioblastoma Multiforme in Their 75th Year or Older Treated With Adjuvant Therapy.” Int J Radiat Oncol Biol Phys 98, no. 4 (July 15, 2017): 802–10. https://doi.org/10.1016/j.ijrobp.2017.02.028.Full Text Link to Item
-
Minckwitz, Gunter von, Marion Procter, Evandro de Azambuja, Dimitrios Zardavas, Mark Benyunes, Giuseppe Viale, Thomas Suter, et al. “Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer.” N Engl J Med 377, no. 2 (July 13, 2017): 122–31. https://doi.org/10.1056/NEJMoa1703643.Full Text Link to Item
-
Tan, Aaron C., Amy B. Heimberger, Alexander M. Menzies, Nick Pavlakis, and Mustafa Khasraw. “Immune Checkpoint Inhibitors for Brain Metastases.” Curr Oncol Rep 19, no. 6 (June 2017): 38. https://doi.org/10.1007/s11912-017-0596-3.Full Text Link to Item
-
Tan, Aaron C., Amy B. Heimberger, and Mustafa Khasraw. “Immune Checkpoint Inhibitors in Gliomas.” Curr Oncol Rep 19, no. 4 (April 2017): 23. https://doi.org/10.1007/s11912-017-0586-5.Full Text Link to Item
-
McDonald, K. L., W. Ha, and M. Khasraw. “P01.20 Treatment of recurrent glioblastoma with the cytokine inhibitor, ibudilast in combination with temozolomide.” Neuro Oncology 19, no. suppl_3 (April 2017): iii27–iii27. https://doi.org/10.1093/neuonc/nox036.096.Full Text
-
Jue, Toni Rose, Kyoko Nozue, Ashleigh J. Lester, Swapna Joshi, Lisette B. W. Schroder, Shane P. Whittaker, Sheri Nixdorf, Robert W. Rapkins, Mustafa Khasraw, and Kerrie L. McDonald. “Veliparib in combination with radiotherapy for the treatment of MGMT unmethylated glioblastoma.” J Transl Med 15, no. 1 (March 17, 2017): 61. https://doi.org/10.1186/s12967-017-1164-1.Full Text Link to Item
-
Lester, A., R. Rapkins, S. Nixdorf, M. Khasraw, and K. McDonald. “Combining PARP inhibitors with radiation therapy for the treatment of glioblastoma: Is PTEN predictive of response?” Clin Transl Oncol 19, no. 3 (March 2017): 273–78. https://doi.org/10.1007/s12094-016-1547-4.Full Text Link to Item
-
Phillips, Claire, Rosalind Jeffree, and Mustafa Khasraw. “Management of breast cancer brain metastases: A practical review.” Breast 31 (February 2017): 90–98. https://doi.org/10.1016/j.breast.2016.10.006.Full Text Link to Item
-
Whittaker, Shane, Daniel Madani, Swapna Joshi, Sylvia A. Chung, Terrance Johns, Bryan Day, Mustafa Khasraw, and Kerrie L. McDonald. “Combination of palbociclib and radiotherapy for glioblastoma.” Cell Death Discov 3 (2017): 17033. https://doi.org/10.1038/cddiscovery.2017.33.Full Text Link to Item
-
Chan, David Lh, Nick Pavlakis, Geoffrey P. Schembri, Elizabeth J. Bernard, Edward Hsiao, Aimee Hayes, Tristan Barnes, et al. “Dual Somatostatin Receptor/FDG PET/CT Imaging in Metastatic Neuroendocrine Tumours: Proposal for a Novel Grading Scheme with Prognostic Significance.” Theranostics 7, no. 5 (2017): 1149–58. https://doi.org/10.7150/thno.18068.Full Text Link to Item
-
Li, Bob T., Tristan A. Barnes, David L. Chan, Jarushka Naidoo, Adrian Lee, Mustafa Khasraw, Gavin M. Marx, et al. “The addition of anti-angiogenic tyrosine kinase inhibitors to chemotherapy for patients with advanced non-small-cell lung cancers: A meta-analysis of randomized trials.” Lung Cancer 102 (December 2016): 21–27. https://doi.org/10.1016/j.lungcan.2016.10.004.Full Text Link to Item
-
Garber, Sarah T., Yuuri Hashimoto, Shiao-Pei Weathers, Joanne Xiu, Zoran Gatalica, Roel G. W. Verhaak, Shouhao Zhou, et al. “Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies.” Neuro Oncol 18, no. 10 (October 2016): 1357–66. https://doi.org/10.1093/neuonc/now132.Full Text Link to Item
-
Sajjad, M Amber, Kara L. Holloway, Mark A. Kotowicz, Patricia M. Livingston, Mustafa Khasraw, Sharon Hakkennes, Trisha L. Dunning, et al. “Ageing, Chronic Disease and Injury: A Study in Western Victoria (Australia).” J Public Health Res 5, no. 2 (August 19, 2016): 678. https://doi.org/10.4081/jphr.2016.678.Full Text Link to Item
-
Segelov, Eva, Subotheni Thavaneswaran, Paul M. Waring, Jayesh Desai, Kristy P. Robledo, Val J. Gebski, Elena Elez, et al. “Response to Cetuximab With or Without Irinotecan in Patients With Refractory Metastatic Colorectal Cancer Harboring the KRAS G13D Mutation: Australasian Gastro-Intestinal Trials Group ICECREAM Study.” J Clin Oncol 34, no. 19 (July 1, 2016): 2258–64. https://doi.org/10.1200/JCO.2015.65.6843.Full Text Link to Item
-
Wann, Alysson, David Ashley, and Mustafa Khasraw. “Use of targeted therapy in cancer patients in the end-of-life period: results from an Australian centre.” Support Care Cancer 24, no. 7 (July 2016): 3023–28. https://doi.org/10.1007/s00520-016-3124-3.Full Text Link to Item
-
Hodges, Tiffany R., Sherise D. Ferguson, Hillary G. Caruso, Gary Kohanbash, Shouhao Zhou, Timothy F. Cloughesy, Mitchel S. Berger, et al. “Prioritization schema for immunotherapy clinical trials in glioblastoma.” Oncoimmunology 5, no. 6 (June 2016): e1145332. https://doi.org/10.1080/2162402X.2016.1145332.Full Text Link to Item
-
Segelov, Eva, Paul Waring, Jayesh Desai, Kate Wilson, Val Gebski, Subotheni Thavaneswaran, Elena Elez, et al. “ICECREAM: randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumours.” Bmc Cancer 16 (May 31, 2016): 339. https://doi.org/10.1186/s12885-016-2389-8.Full Text Link to Item
-
Khasraw, Mustafa, Adrian Lee, Sally McCowatt, Zoltan Kerestes, Marc E. Buyse, Michael Back, Ganessan Kichenadasse, Stephen Ackland, and Helen Wheeler. “Cilengitide with metronomic temozolomide, procarbazine, and standard radiotherapy in patients with glioblastoma and unmethylated MGMT gene promoter in ExCentric, an open-label phase II trial.” J Neurooncol 128, no. 1 (May 2016): 163–71. https://doi.org/10.1007/s11060-016-2094-0.Full Text Link to Item
-
Wong, Shu Fen, Leigh Matheson, Kate Morrissy, Graham Pitson, David M. Ashley, Mustafa Khasraw, Paula K. Lorgelly, and Margaret J. Henry. “Retrospective analysis of cancer survival across South-Western Victoria in Australia.” Aust J Rural Health 24, no. 2 (April 2016): 79–84. https://doi.org/10.1111/ajr.12203.Full Text Link to Item
-
Wong, Shu Fen, Richard Norman, Trisha Lynette Dunning, David Michael Ashley, Mustafa Khasraw, Theresa Margaret Hayes, Ian Collins, and Paula Kate Lorgelly. “A Discrete Choice Experiment to Examine the Preferences of Patients With Cancer and Their Willingness to Pay for Different Types of Health Care Appointments.” J Natl Compr Canc Netw 14, no. 3 (March 2016): 311–19. https://doi.org/10.6004/jnccn.2016.0036.Full Text Link to Item
-
Field, K. M., M. A. Rosenthal, M. Khasraw, K. Sawkins, and A. K. Nowak. “Evolving management of low grade glioma: No consensus amongst treating clinicians.” J Clin Neurosci 23 (January 2016): 81–87. https://doi.org/10.1016/j.jocn.2015.05.038.Full Text Link to Item
-
Khasraw, Mustafa, Sumitra Ananda, and Michael Michael. “Neuroendocrine tumors of the gastrointestinal tract and the role of cytotoxic chemotherapy.” Expert Rev Anticancer Ther 16, no. 4 (2016): 391–401. https://doi.org/10.1586/14737140.2016.1146135.Full Text Link to Item
-
McDonald, Kerrie, Swapna Joshi, Toni Rose Jue, Julia Yin, and Mustafa Khasraw. “ATPS-54GENOMICALLY UNSTABLE GLIOBLASTOMA (U-GBM) SHOW EXQUISITE SENSITIVITY TO PARP INHIBITION.” Neuro Oncology 17, no. Suppl 5 (November 9, 2015): v30–v30. https://doi.org/10.1093/neuonc/nov204.54.Full Text
-
Dukelow, Tim, Divya Kishan, Mustafa Khasraw, and Conleth G. Murphy. “CDK4/6 inhibitors in breast cancer.” Anticancer Drugs 26, no. 8 (September 2015): 797–806. https://doi.org/10.1097/CAD.0000000000000249.Full Text Link to Item
-
Turner, Nicholas C., Jungsil Ro, Fabrice André, Sherene Loi, Sunil Verma, Hiroji Iwata, Nadia Harbeck, et al. “Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer.” N Engl J Med 373, no. 3 (July 16, 2015): 209–19. https://doi.org/10.1056/NEJMoa1505270.Full Text Link to Item
-
Wang, Tao, Michael P. Gantier, Dongxi Xiang, Andrew G. Bean, Matthew Bruce, Shu-Feng Zhou, Mustafa Khasraw, et al. “EpCAM Aptamer-mediated Survivin Silencing Sensitized Cancer Stem Cells to Doxorubicin in a Breast Cancer Model.” Theranostics 5, no. 12 (2015): 1456–72. https://doi.org/10.7150/thno.11692.Full Text Link to Item
-
Khasraw, M., S. M. Patil, T. A. Traina, and M. E. Robson. “Poly(ADP-Ribose) Polymerase (PARP) Inhibitors for locally advanced or metastatic breast cancer.” Cochrane Database of Systematic Reviews 2014, no. 11 (November 26, 2014). https://doi.org/10.1002/14651858.CD011395.Full Text
-
Wann, Alysson, David M. Ashley, and Mustafa Khasraw. “Use of targeted therapy in cancer patients in the end-of-life period.” Journal of Clinical Oncology 32, no. 31_suppl (November 1, 2014): 129–129. https://doi.org/10.1200/jco.2014.32.31_suppl.129.Full Text
-
Cosman, Rasha, Christopher S. B. Brown, Kevin C. DeBraganca, and Mustafa Khasraw. “Patterns of care in adult medulloblastoma: results of an international online survey.” J Neurooncol 120, no. 1 (October 2014): 125–29. https://doi.org/10.1007/s11060-014-1525-z.Full Text Link to Item
-
Khasraw, Mustafa, Malaka S. Ameratunga, Robin Grant, Helen Wheeler, and Nick Pavlakis. “Antiangiogenic therapy for high-grade glioma.” Cochrane Database Syst Rev, no. 9 (September 22, 2014): CD008218. https://doi.org/10.1002/14651858.CD008218.pub3.Full Text Link to Item
-
Ameratunga, Malaka, Nick Pavlakis, Val Gebski, Adam Broad, and Mustafa Khasraw. “Epidermal growth factor receptor-tyrosine kinase inhibitors in advanced squamous cell carcinoma of the lung: a meta-analysis.” Asia Pac J Clin Oncol 10, no. 3 (September 2014): 273–78. https://doi.org/10.1111/ajco.12231.Full Text Link to Item
-
Khasraw, Mustafa, Malaka Ameratunga, and Christian Grommes. “Bevacizumab for the treatment of high-grade glioma: an update after phase III trials.” Expert Opin Biol Ther 14, no. 5 (May 2014): 729–40. https://doi.org/10.1517/14712598.2014.898060.Full Text Link to Item
-
Gupta, Sunil, Truyen Tran, Wei Luo, Dinh Phung, Richard Lee Kennedy, Adam Broad, David Campbell, et al. “Machine-learning prediction of cancer survival: a retrospective study using electronic administrative records and a cancer registry.” Bmj Open 4, no. 3 (March 17, 2014): e004007. https://doi.org/10.1136/bmjopen-2013-004007.Full Text Link to Item
-
Sim, Hao-Wen, Patrick G. Morris, Sujata Patil, and Mustafa Khasraw. “Brain metastases in breast cancer.” Expert Rev Anticancer Ther 14, no. 2 (February 2014): 173–83. https://doi.org/10.1586/14737140.2014.863468.Full Text Link to Item
-
Davis, Justin, Fiona M. Ahlberg, Michael Berk, David M. Ashley, and Mustafa Khasraw. “Emerging pharmacotherapy for cancer patients with cognitive dysfunction.” Bmc Neurol 13 (October 24, 2013): 153. https://doi.org/10.1186/1471-2377-13-153.Full Text Link to Item
-
Mustafa, Barzin F., Mark Samaan, Louise Langmead, and Mustafa Khasraw. “Small bowel video capsule endoscopy: an overview.” Expert Rev Gastroenterol Hepatol 7, no. 4 (May 2013): 323–29. https://doi.org/10.1586/egh.13.20.Full Text Link to Item
-
Khasraw, Mustafa, Saw Yee Yap, and Sumitra Ananda. “Neuroendocrine neoplasms of the GI tract: the role of cytotoxic chemotherapy.” Expert Rev Anticancer Ther 13, no. 4 (April 2013): 451–59. https://doi.org/10.1586/era.13.22.Full Text Link to Item
-
Domchek, Susan M., Komal Jhaveri, Sujata Patil, Jill E. Stopfer, Clifford Hudis, Jacquelyn Powers, Zsofia Stadler, et al. “Risk of metachronous breast cancer after BRCA mutation-associated ovarian cancer.” Cancer 119, no. 7 (April 1, 2013): 1344–48. https://doi.org/10.1002/cncr.27842.Full Text Link to Item
-
Harvey, Sandra L., and Mustafa Khasraw. “Alternative targeted therapy for early Her2 positive breast cancer.” Gland Surg 2, no. 1 (February 2013): 42–45. https://doi.org/10.3978/j.issn.2227-684X.2013.02.06.Full Text Link to Item
-
Omuro, Antonio, Timothy A. Chan, Lauren E. Abrey, Mustafa Khasraw, Anne S. Reiner, Thomas J. Kaley, Lisa M. Deangelis, et al. “Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma.” Neuro Oncol 15, no. 2 (February 2013): 242–50. https://doi.org/10.1093/neuonc/nos295.Full Text Link to Item
-
Lomax, Anna J., Saw Yee Yap, and Mustafa Khasraw. “Intra-aortic metastases or intra-arterial thrombus?” International Journal of Case Reports and Images 4, no. 7 (2013): 368–368. https://doi.org/10.5348/ijcri-2013-07-333-7.Full Text
-
Sheet, Shatha Yousif, Anwar K. Sheikha, Ahmed M. Saeed, Hazha Abdulla M. Ameen, Samir Saleh Mohammed, and Mustafa Khasraw. “Colorectal cancer: is the incidence rising in young Iraqi patients?” Asia Pac J Clin Oncol 8, no. 4 (December 2012): 380–81. https://doi.org/10.1111/j.1743-7563.2012.01524.x.Full Text Link to Item
-
Khasraw, Mustafa, David Ashley, Greg Wheeler, and Michael Berk. “Using lithium as a neuroprotective agent in patients with cancer.” Bmc Med 10 (November 2, 2012): 131. https://doi.org/10.1186/1741-7015-10-131.Full Text Link to Item
-
Khasraw, Mustafa, and Richard Bell. “Primary systemic therapy in HER2-amplified breast cancer: a clinical review.” Expert Rev Anticancer Ther 12, no. 8 (August 2012): 1005–13. https://doi.org/10.1586/era.12.62.Full Text Link to Item
-
Khasraw, Mustafa, Marcelle Simeonovic, and Christian Grommes. “Bevacizumab for the treatment of high-grade glioma.” Expert Opin Biol Ther 12, no. 8 (August 2012): 1101–11. https://doi.org/10.1517/14712598.2012.694422.Full Text Link to Item
-
Khasraw, Mustafa, Richard Bell, and Chau Dang. “Epirubicin: is it like doxorubicin in breast cancer? A clinical review.” Breast 21, no. 2 (April 2012): 142–49. https://doi.org/10.1016/j.breast.2011.12.012.Full Text Link to Item
-
Khasraw, M., S. L. Harvey, and R. Bell. “Hormonal resistance in breast cancer: Evolving treatment strategies.” Current Breast Cancer Reports 4, no. 1 (March 1, 2012): 66–74. https://doi.org/10.1007/s12609-011-0065-1.Full Text
-
Khasraw, M., A. Holodny, S. A. Goldlust, and L. M. DeAngelis. “Intracranial hemorrhage in patients with cancer treated with bevacizumab: the Memorial Sloan-Kettering experience.” Ann Oncol 23, no. 2 (February 2012): 458–63. https://doi.org/10.1093/annonc/mdr148.Full Text Link to Item
-
Khasraw, Mustafa, and Mark Robson. “Poly(ADP-ribose) polymerase inhibitors in breast cancer and other tumors: advances and challenges.” Clinical Investigation 1, no. 11 (November 2011): 1545–54. https://doi.org/10.4155/cli.11.132.Full Text
-
Khasraw, Mustafa, Edi Brogi, and Andrew D. Seidman. “The need to examine metastatic tissue at the time of progression of breast cancer: is re-biopsy a necessity or a luxury?” Curr Oncol Rep 13, no. 1 (February 2011): 17–25. https://doi.org/10.1007/s11912-010-0137-9.Full Text Link to Item
-
Khasraw, Mustafa, and Jerome B. Posner. “Neurological complications of systemic cancer.” Lancet Neurol 9, no. 12 (December 2010): 1214–27. https://doi.org/10.1016/S1474-4422(10)70220-9.Full Text Link to Item
-
Khasraw, M., H. Faraj, and A. Sheikha. “Thrombocytopenia in solid tumors.” European Journal of Clinical and Medical Oncology 2, no. 2 (September 9, 2010).
-
Murphy, C. G., M. Khasraw, and A. D. Seidman. “Holding back the sea: the role for maintenance chemotherapy in metastatic breast cancer.” Breast Cancer Res Treat 122, no. 1 (July 2010): 177–79. https://doi.org/10.1007/s10549-010-0925-9.Full Text Link to Item
-
Khasraw, M., A. Townsend, T. Price, J. Hart, D. Bell, and N. Pavlakis. “Objective radiological disease control with sandostatin monotherapy in metastatic neuroendocrine tumours.” Intern Med J 40, no. 6 (June 2010): 453–58. https://doi.org/10.1111/j.1445-5994.2010.02245.x.Full Text Link to Item
-
Khasraw, M., N. Pavlakis, S. McCowatt, C. Underhill, S. Begbie, P. de Souza, A. Boyce, et al. “Multicentre phase I/II study of PI-88, a heparanase inhibitor in combination with docetaxel in patients with metastatic castrate-resistant prostate cancer.” Ann Oncol 21, no. 6 (June 2010): 1302–7. https://doi.org/10.1093/annonc/mdp524.Full Text Link to Item
-
Khasraw, Mustafa, Andrew B. Lassman, Helen Wheeler, and Nick Pavlakis. “Anti-angiogenic therapy for high grade glioma.” Edited by Mustafa Khasraw, February 17, 2010. https://doi.org/10.1002/14651858.cd008218.pub2.Full Text
-
Khasraw, Mustafa, and Andrew B. Lassman. “Advances in the treatment of malignant gliomas.” Curr Oncol Rep 12, no. 1 (January 2010): 26–33. https://doi.org/10.1007/s11912-009-0077-4.Full Text Link to Item
-
Gifford, Andrew J., Phoebe S. Jones, Mustafa Khasraw, Stuart Kostalas, and Anthony J. Gill. “16. Primary choriocarcinoma of the colon – a case report.” Pathology 42 (2010): S85–86. https://doi.org/10.1097/01268031-201042001-00187.Full Text
-
Khasraw, M., C. Atkinson, D. Van Der Saag, N. Pavlakis, and A. Guminski. “Cardiac toxicity from sunitinib: Do we need to be more vigilant?” Asia Pacific Journal of Clinical Oncology 5, no. 4 (December 15, 2009): 217–18. https://doi.org/10.1111/j.1743-7563.2009.01243.x.Full Text
-
Khasraw, Mustafa, and Andrew B. Lassman. “Neuro-oncology: late neurocognitive decline after radiotherapy for low-grade glioma.” Nat Rev Neurol 5, no. 12 (December 2009): 646–47. https://doi.org/10.1038/nrneurol.2009.194.Full Text Link to Item
-
Pavlakis, Nick, Gavin Marx, Shane White, Christopher W. Lee, and Mustafa Khasraw. “Anti-angiogenic therapy for lung cancer.” Cochrane Database of Systematic Reviews, October 7, 2009. https://doi.org/10.1002/14651858.cd008047.Full Text
-
Khasraw, Mustafa, Anthony Gill, Tim Harrington, Nick Pavlakis, and Irvin Modlin. “Management of advanced neuroendocrine tumors with hepatic metastasis.” J Clin Gastroenterol 43, no. 9 (October 2009): 838–47. https://doi.org/10.1097/MCG.0b013e3181b152a1.Full Text Link to Item
-
Khasraw, M., and S. Baron-Hay. “Immune thrombocytopenic purpura (ITP) and breast cancer. Does adjuvant therapy for breast cancer improve platelet counts in ITP?” Ann Oncol 20, no. 7 (July 2009): 1282–83. https://doi.org/10.1093/annonc/mdp305.Full Text Link to Item
-
Khasraw, Mustafa, David Bell, and Helen Wheeler. “Long-term use of temozolomide: could you use temozolomide safely for life in gliomas?” J Clin Neurosci 16, no. 6 (June 2009): 854–55. https://doi.org/10.1016/j.jocn.2008.09.005.Full Text Link to Item
-
Perrone, Francesco, Ciro Gallo, and Bruno Daniele. “Chemotherapy in the elderly.” N Engl J Med 346, no. 8 (February 21, 2002): 622–23. https://doi.org/10.1056/NEJM200202213460814.Full Text Link to Item
-
-
Book Sections
-
Khasraw, M., A. Noy, M. Gilbert, and A. Omuro. “Neurological complications of non-hodgkin lymphoma.” In Lymphoma and Leukemia of the Nervous System, 267–85, 2012. https://doi.org/10.1007/9781441976680_16.Full Text
-
Khasraw, Mustafa, Ariela Noy, Mark Gilbert, and Antonio Omuro. “Neurological Complications of Non-Hodgkin Lymphoma.” In Lymphoma and Leukemia of the Nervous System, 267–85. Springer New York, 2012. https://doi.org/10.1007/978-1-4419-7668-0_16.Full Text
-
Khasraw, Mustafa, and Yasmin Khakoo. “Paraneoplastic Syndromes Affecting the Nervous System.” In Swaiman’s Pediatric Neurology, 1388–94. Elsevier, 2012. https://doi.org/10.1016/b978-1-4377-0435-8.00101-3.Full Text
-
-
Conference Papers
-
Johnson, Margaret, Mustafa Khasraw, Jung-Young Kim, Nicole Cort, James Herndon, Luis Ramirez, Eric Lipp, et al. “QOLP-28. COMPARING KNOWLEDGE OF AND BELIEFS ABOUT PALLIATIVE CARE AMONG NEURO-ONCOLOGY PATIENTS, CAREGIVERS, PROVIDERS AND A NATIONALLY-REPRESENTATIVE U.S. SAMPLE.” In Neuro Oncology, 23:vi189–vi189. Oxford University Press (OUP), 2021. https://doi.org/10.1093/neuonc/noab196.748.Full Text Open Access Copy Link to Item
-
Peters, Katherine, Mallika Patel, Candice Alford, Gerardo Chavez, Jung-Young Kim, Jennifer Durling, Tracy Novack, et al. “INNV-20. RADIOGRAPHIC RESPONSE AND SEIZURE CONTROL IN IDH1 MUTANT GLIOMA PATIENTS USING IVOSIDENIB.” In Neuro Oncology, 23:vi109–vi109. Oxford University Press (OUP), 2021. https://doi.org/10.1093/neuonc/noab196.431.Full Text Open Access Copy Link to Item
-
Petitt, Zoey, James Herndon, Oren Gottfried, Christina Cone, Daniel Landi, Mustafa Khasraw, Henry Friedman, et al. “INNV-31. NEURO-ONCOLOGY OUTPATIENT SATISFACTION IS MAINTAINED IN THE ERA OF COVID-19 TELEMEDICINE.” In Neuro Oncology, 23:vi112–vi112. Oxford University Press (OUP), 2021. https://doi.org/10.1093/neuonc/noab196.442.Full Text Open Access Copy
-
Sim, Hao-Wen, Kerrie L. McDonald, Zarnie Lwin, Elizabeth H. Barnes, Mark Rosenthal, Matthew C. Foote, Eng-Siew Koh, et al. “A randomized phase II trial of veliparib, radiotherapy, and temozolomide in patients with unmethylated MGMT glioblastoma: the VERTU study.” In Neuro Oncol, 23:1736–49, 2021. https://doi.org/10.1093/neuonc/noab111.Full Text Link to Item
-
Thompson, Eric, Daniel Landi, Gerald Archer, Eric Lipp, Ashley Walter, Bridget Archambault, Bea Balajonda, et al. “EPCT-01. A NOVEL PEPTIDE VACCINE DIRECTED TO CMV PP65 FOR TREATMENT OF RECURRENT MALIGNANT GLIOMA AND MEDULLOBLASTOMA IN CHILDREN AND YOUNG ADULTS: PRELIMINARY RESULTS OF A PHASE I TRIAL.” In Neuro Oncology, 23:i46–i46. Oxford University Press (OUP), 2021. https://doi.org/10.1093/neuonc/noab090.187.Full Text Link to Item
-
Sammons, Sarah, Andrew Elliott, Jeremy Meyer Force, Nicholas C. DeVito, Paul Kelly Marcom, Sandra M. Swain, Antoinette R. Tan, et al. “Genomic evaluation of tumor mutational burden-high (TMB-H) versus TMB-low (TMB-L) metastatic breast cancer to reveal unique mutational features.” In Journal of Clinical Oncology, 39:1091–1091. American Society of Clinical Oncology (ASCO), 2021. https://doi.org/10.1200/jco.2021.39.15_suppl.1091.Full Text
-
Sanborn, Rachel E., Rodolfo Eduardo Bordoni, Gini F. Fleming, Mustafa Khasraw, Thomas Hawthorne, Lawrence J. Thomas, Tracey Rawls, et al. “A phase 1 dose-escalation study of a PD-L1xCD27 bispecific antibody CDX-527 in patients with advanced malignancies.” In Journal of Clinical Oncology, 39:2585–2585. American Society of Clinical Oncology (ASCO), 2021. https://doi.org/10.1200/jco.2021.39.15_suppl.2585.Full Text
-
Wen, Patrick Y., Ingo K. Mellinghoff, Meredith Becker Buxton, Webster K. Cavenee, Howard Colman, John Frederick De Groot, Benjamin M. Ellingson, et al. “GBM AGILE: A global, phase 2/3 adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma.” In Journal of Clinical Oncology, 39:TPS2074–TPS2074. American Society of Clinical Oncology (ASCO), 2021. https://doi.org/10.1200/jco.2021.39.15_suppl.tps2074.Full Text
-
Batich, Kristen, Duane Mitchell, Patrick Healy, James Herndon, Gloria Broadwater, Gunn Michael, Min-Nung Huang, et al. “REPRODUCIBILITY OF CLINICAL TRIALS USING CMV-TARGETED DENDRITIC CELL VACCINES IN PATIENTS WITH GLIOBLASTOMA.” In Neuro Oncology, 23:51–51, 2021.Link to Item
-
Brown, Michael, Gao Zhang, Kevin Stevenson, Xiang Lin, Yeqing Chen, Zhi Wei, Nike Beaubier, et al. “TUMOR-INTRINSIC AND PERIPHERAL FEATURES ASSOCIATE WITH SURVIVAL AFTER POLIO VIROTHERAPY IN RECURRENT GBM.” In Neuro Oncology, 23:14–14, 2021.Link to Item
-
Johnson, Margaret, Mustafa Khasraw, Jung-Young Kim, Nicole Cort, James Herndon, Luis Ramirez, Eric Lipp, et al. “COMPARING KNOWLEDGE OF AND BELIEFS ABOUT PALLIATIVE CARE AMONG NEURO-ONCOLOGY PATIENTS, CAREGIVERS, PROVIDERS AND A NATIONALLY-REPRESENTATIVE US SAMPLE.” In Neuro Oncology, 23:189–189, 2021.Link to Item
-
Kong, Benjamin, Hao-Wen Sim, Benhur Amanuel, Bryan Day, Michael Buckland, Roel Verhaak, Sonia Yip, et al. “LOW AND INTERMEDIATE GRADE GLIOMA UMBRELLA STUDY OF MOLECULAR GUIDED THERAPIES (LUMOS) STUDY.” In Neuro Oncology, 23:106–106, 2021.Link to Item
-
Ostrom, Quinn, Joanne Xiu, Giselle Lopez, Ashley Sumrall, Sonikpreet Aulakh, Michael Glantz, Edward Pan, Mustafa Khasraw, David M. Ashley, and Kyle Walsh. “DIFFERENCES IN THE IMMUNE MICROENVIRONMENT OF GLIOMAS HARBORING IDH2 VERSUS IDH1 MUTATIONS.” In Neuro Oncology, 23:13–14, 2021.Link to Item
-
Peters, Katherine, Mallika Patel, Candice Alford, Gerardo Chavez, Jung-Young Kim, Jennifer Durling, Tracy Novack, et al. “RADIOGRAPHIC RESPONSE AND SEIZURE CONTROL IN IDH1 MUTANT GLIOMA PATIENTS USING IVOSIDENIB.” In Neuro Oncology, 23:109–109, 2021.Link to Item
-
Peters, Katherine, Mary Affronti, Jung-Young Kim, Mallika Patel, Margaret Johnson, David Bartlett, Nicole Cort, et al. “A LONGITUDINAL OBSERVATIONAL STUDY OF EXERCISE BEHAVIOR IN GLIOBLASTOMA PATIENTS TREATED WITH TUMOR-TREATING FIELDS.” In Neuro Oncology, 23:184–85, 2021.Link to Item
-
Petitt, Zoey, James Herndon, Oren Gottfried, Christina Cone, Daniel Landi, Mustafa Khasraw, Henry Friedman, et al. “NEURO-ONCOLOGY OUTPATIENT SATISFACTION IS MAINTAINED IN THE ERA OF COVID-19 TELEMEDICINE.” In Neuro Oncology, 23:112–112, 2021.Link to Item
-
Singh, Kirit, Patrick Gedeon, Teilo Schaller, David Snyder, Mustafa Khasraw, and John Sampson. “T CELL HITCHHIKING AS A MECHANISM OF DRUG DELIVERY TO THE BRAIN.” In Neuro Oncology, 23:182–182, 2021.Link to Item
-
Varn, Frederick, Kevin Johnson, Taylor Wade, Tathiane Malta, Thais Sabedot, Floris Barthel, Hoon Kim, et al. “LONGITUDINAL ANALYSIS OF DIFFUSE GLIOMA REVEALS CELL STATE DYNAMICS AT RECURRENCE ASSOCIATED WITH CHANGES IN GENETICS AND THE MICROENVIRONMENT.” In Neuro Oncology, 23:3–3, 2021.Link to Item
-
Thompson, Eric, Daniel Landi, Eric Lipp, Bea Balajonda, James Herndon, Evan Buckley, Charlene Flahiff, et al. “CTIM-21. PEPTIDE VACCINE DIRECTED TO CMV pp65 FOR TREATMENT OF RECURRENT MALIGNANT GLIOMA AND MEDULLOBLASTOMA IN CHILDREN AND YOUNG ADULTS: PRELIMINARY RESULTS OF A PHASE I TRIAL.” In Neuro Oncology, 22:ii37–ii37. Oxford University Press (OUP), 2020. https://doi.org/10.1093/neuonc/noaa215.155.Full Text Open Access Copy Link to Item
-
Yap, Timothy A., Panagiotis Konstantinopoulos, Melinda L. Telli, Smita Saraykar, J Thaddeus Beck, Matthew D. Galsky, Jame Abraham, et al. “Abstract P1-19-03: JAVELIN PARP Medley, a phase 1b/2 study of avelumab plus talazoparib: Results from advanced breast cancer cohorts.” In Cancer Research, Vol. 80. American Association for Cancer Research (AACR), 2020. https://doi.org/10.1158/1538-7445.sabcs19-p1-19-03.Full Text
-
Buxton, Meredith Becker, Brian Michael Alexander, Donald A. Berry, Webster K. Cavenee, Howard Colman, John Frederick De Groot, Benjamin M. Ellingson, et al. “GBM AGILE: A global, phase II/III adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma.” In Journal of Clinical Oncology, Vol. 38, 2020.Link to Item
-
Buxton, Meredith, Brian Alexander, Donald Berry, Webster Cavenee, Howard Colman, John de Groot, Benjamin Ellingson, et al. “GBM AGILE: A GLOBAL, PHASE 2/3 ADAPTIVE PLATFORM TRIAL TO EVALUATE MULTIPLE REGIMENS IN NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA.” In Neuro Oncology, 22:195–96, 2020.Link to Item
-
Cort, Nicole, Alex Broom, Katherine Kenny, Alexander Page, Jennifer Durling, Casey Brown, Eric Lipp, et al. “THE PARADOXICAL EFFECTS OF COVID-19 ON CANCER CARE IN THE NEURO-ONCOLOGY SETTING.” In Neuro Oncology, 22:26–26, 2020.Link to Item
-
Desjardins, Annick, Dina Randazzo, Vidya Chandramohan, Katherine Peters, Margaret Johnson, Daniel Landi, Mustafa Khasraw, et al. “A PHASE 1 TRIAL OF D2C7-IT IN COMBINATION WITH ATEZOLIZUMAB IN RECURRENT WHO GRADE IV MALIGNANT GLIOMA (MG).” In Neuro Oncology, 22:38–38, 2020.Link to Item
-
Thompson, Eric, Daniel Landi, Eric Lipp, Bea Balajonda, James I. I. Herndon, Evan Buckley, Charlene Flahiff, et al. “PEPTIDE VACCINE DIRECTED TO CMV PP65 FOR TREATMENT OF RECURRENT MALIGNANT GLIOMA AND MEDULLOBLASTOMA IN CHILDREN AND YOUNG ADULTS: PRELIMINARY RESULTS OF A PHASE I TRIAL.” In Neuro Oncology, 22:37–37, 2020.Link to Item
-
Walsh, Kyle, Joanne Xiu, Giselle Lopez, Daniel Landi, Zachary Reitman, Sandeep Mittal, Andrew Brenner, et al. “BRAF MUTATION IS AN EARLY EVENT IN THE EVOLUTION OF A SUBSET OF GLIOBLASTOMAS AND IS ASSOCIATED WITH INCREASED PD-L1 EXPRESSION.” In Neuro Oncology, 22:5–5, 2020.Link to Item
-
Anderson, Kevin, Aaron Tan, Jonathon Parkinson, Michael Back, Marina Kastela, Allison Newey, Janice Brewer, et al. “MOLECULAR AND CLONAL EVOLUTION IN RECURRENT METASTATIC GLIOSARCOMA.” In Neuro Oncology, 21:64–64. OXFORD UNIV PRESS INC, 2019.Link to Item
-
De Silva, Madhawa, Adrian Lee, Marina Kastela, Helen Wheeler, and Mustafa Khasraw. “A SERIES OF PATIENTS (PTS) WITH RECURRENT GBM (rGBM) TREATED WITH ABT-414, BEVACIZUMAB (BEV) AND CCNU.” In Neuro Oncology, 21:19–19. OXFORD UNIV PRESS INC, 2019.Link to Item
-
Poisson, Laila, M. C. M. Kouwenhoven, James Snyder, Kristin Alfaro-Munoz, Manpreet Kaur, Amanda Bates, Roel Verhaak, et al. “PURSUIT OF AN INTERNATIONAL LANGUAGE OF GLIOMA RESEARCH: COMMON DATA ELEMENTS FOR THE LONGITUDINAL STUDY OF ADULT MALIGNANT GLIOMA.” In Neuro Oncology, 21:79–79. OXFORD UNIV PRESS INC, 2019.Link to Item
-
Rosenthal, Mark A., Carmen Balana, Myra E. van Linde, Cyrus Sayehli, Walter M. Fiedler, Martin Wermke, Christophe Massard, et al. “AMG 596, A NOVEL ANTI-EGFRVIII BISPECIFIC T CELL ENGAGER (BITE (R)) MOLECULE FOR THE TREATMENT OF GLIOBLASTOMA (GBM): PLANNED INTERIM ANALYSIS IN RECURRENT GBM (RGBM).” In Neuro Oncology, 21:283–283. OXFORD UNIV PRESS INC, 2019.Link to Item
-
Luke, J. J., L. Fong, K. Chung, A. W. Tolcher, K. Kelly, A. Hollebecque, C. Le Tourneau, et al. “Phase I study evaluating safety, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of ABBV-428, first-in-class mesothelin (MSLN)-CD40 bispecific, in patients (pts) with advanced solid tumours.” In Annals of Oncology, Vol. 30. OXFORD UNIV PRESS, 2019.Link to Item
-
Yip, Sonia, Martin Stockler, Desmond Yip, Anna Nowak, Paul Mitchell, Yoland Antill, Daniel Andrews, et al. “Molecular Determinants of Autoimmunity and Immune Related Adverse Events in Advanced Cancer Patients Treated with Immune Checkpoint Inhibitors (Auto-Check Study).” In Asia Pacific Journal of Clinical Oncology, 15:59–59. WILEY, 2019.Link to Item
-
Khasraw, Mustafa, Kerrie Leanne McDonald, Mark Rosenthal, Zarnie Lwin, David M. Ashley, Helen Wheeler, Elizabeth Barnes, et al. “A randomized phase II trial of veliparib (V), radiotherapy (RT) and temozolomide (TMZ) in patients (pts) with unmethylated MGMT (uMGMT) glioblastoma (GBM).” In Journal of Clinical Oncology, 37:2011–2011. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/jco.2019.37.15_suppl.2011.Full Text
-
Sim, Hao-Wen, Elizabeth Barnes, Zarnie Lwin, Mark Rosenthal, Helen Wheeler, Eng-Siew Koh, Matthew C. Foote, et al. “Health-related quality of life (HRQL) in VERTU: A randomized phase II trial of veliparib (V), radiotherapy (RT), and temozolomide (TMZ) for newly diagnosed MGMT unmethylated (uMGMT) glioblastoma (GBM).” In Journal of Clinical Oncology, 37:2042–2042. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/jco.2019.37.15_suppl.2042.Full Text
-
Bailey, Dale, David Chan, Paul Roach, Geoffrey Schembri, Elizabeth Bernard, Edward Hsiao, Aimee Hayes, Mustafa Khasraw, Jaswinda Samra, and Nick Pavlakis. “The Prognostic Impact of Dual FDG/Somatostatin Receptor PET in Metastatic Neuroendocrine Tumours: Updated Overall Survival from the NFTPFT Study.” In Journal of Nuclear Medicine, Vol. 60. SOC NUCLEAR MEDICINE INC, 2019.Link to Item
-
Ameratunga, Malaka, Nick Pavlakis, Helen Wheeler, Robin Grant, John Simes, and Mustafa Khasraw. “ANTI-ANGIOGENIC THERAPY FOR HIGH-GRADE GLIOMA: A META-ANALYSIS.” In Neuro Oncology, 20:82–83. OXFORD UNIV PRESS INC, 2018.Link to Item
-
Khasraw, Mustafa, Kerrie L. McDonald, Sonia Yip, Roel Verhaak, Amy Heimberger, Merryn Hall, Lauren Fisher, et al. “NUTMEG: A randomised phase II study of nivolumab and temozolomide (TMZ) versus TMZ alone in elderly patients with newly diagnosed glioblastoma (GBM): Trial in progress.” In Asia Pacific Journal of Clinical Oncology, 14:196–97. WILEY, 2018.Link to Item
-
Khasraw, Mustafa, Kerrie McDonald, Sonia Yip, Roel Verhaak, Amy Heimberger, Merryn Hall, Lauren Fisher, et al. “NUTMEG: A RANDOMISED PHASE II STUDY OF NIVOLUMAB AND TEMOZOLOMIDE (TMZ) VS TMZ ALONE IN ELDERLY PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM): TRIAL IN PROGRESS.” In Neuro Oncology, 20:235–235. OXFORD UNIV PRESS INC, 2018.Link to Item
-
Khasraw, Mustafa, Michael Weller, David Lorente Estelles, Kathryn Kolibaba, Chee Lee, Craig Gedye, Macarena De La Fuente, et al. “PHASE 1 STUDY RESULTS OF M7824 (MSB0011359C), A BIFUNCTIONAL FUSION PROTEIN TARGETING TGF- AND PD-L1, AMONG PATIENTS WITH RECURRENT GLIOBLASTOMA (rGBM).” In Neuro Oncology, 20:4–4. OXFORD UNIV PRESS INC, 2018.Link to Item
-
Nowak, Anna K., Sonia Yip, Martin Stockler, Desmond Yip, Paul Mitchell, Yoland Antill, Daniel Andrews, et al. “Molecular determinants of autoimmunity and immune related adverse events in advanced cancer patients treated with immune checkpoint inhibitors (AUTO-CHECK study).” In Asia Pacific Journal of Clinical Oncology, 14:152–152. WILEY, 2018.Link to Item
-
Khasraw, M., K. McDonald, S. Yip, R. G. Verhaak, A. B. Heimberger, M. Hall, E. Barnes, E. Hovey, B. M. Ellingson, and Z. Lwin. “NIVOLUMAB AND TEMOZOLOMIDE (TMZ) VS TMZ ALONE IN NEWLY DIAGNOSED ELDERLY PATIENTS (PTS) WITH GLIOBLASTOMA (GBM) (NUTMEG): TRIAL IN PROGRESS.” In Neuro Oncology, 20:236–236. OXFORD UNIV PRESS INC, 2018.Link to Item
-
Khasraw, Mustafa, Kerrie Leanne McDonald, Mark Rosenthal, Zarnie Lwin, David M. Ashley, Helen Wheeler, Elizabeth Barnes, et al. “A randomized phase 2 trial of veliparib (V), radiotherapy (RT) and temozolomide (TMZ) in patients (pts) with unmethylated MGMT (uMGMT) glioblastoma (GBM): Feasibility and safety outcomes (the VERTU study).” In Journal of Clinical Oncology, 36:2045–2045. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.15_suppl.2045.Full Text
-
Tio, Martin, Sujata Patil, Tiffany A. Traina, Mark E. Robson, and Mustafa Khasraw. “Poly(ADP-Ribose) Polymerase Inhibitors (PARPi) for patients (pts) with locally advanced or metastatic breast cancer (BC): A meta-analysis.” In Journal of Clinical Oncology, 36:1076–1076. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.15_suppl.1076.Full Text
-
Chantrill, Lorraine A., Lara Rachel Lipton, Michael Hofman, Val Gebski, Anthony Gill, Ben Markman, Sonia Yip, et al. “AGITG nabnec: A randomised phase II study of nab-paclitaxel in combination with carboplatin as first line treatment of gastrointestinal neuroendocrine carcinomas.” In Journal of Clinical Oncology, 36:TPS548–TPS548. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.4_suppl.tps548.Full Text
-
Ferguson, Sherise, Siyuan Zheng, Joanne Xiu, Shouhao Zhou, Mustafa Khasraw, Priscilla K. Brastianos, Santosh Kesari, et al. “PAN-CANCER PROFILES OF BRAIN METASTASES: PRIORITIZATION OF THERAPEUTIC TARGETS.” In Neuro Oncology, 19:40–41. OXFORD UNIV PRESS INC, 2017.Link to Item
-
Khasraw, Mustafa, Lara Lipton, Michael Hofman, Val Gebski, Anthony Gill, Ben Markman, Sonia Yip, et al. “Agitg Nabnec: A Randomised Phase II Study of NAB-Paclitaxel in Combination With Carboplatin as First-Line Treatment of Gastrointestinal Neuroendocrine Carcinomas.” In Asia Pacific Journal of Clinical Oncology, 13:166–67. WILEY, 2017.Link to Item
-
Vasista, Anuradha, Andrew Martin, Nick Pavlakis, Katrin M. Sjoquist, Stephanie Snow, Derek Jonker, Yu Jo Chua, et al. “Accuracy and Prognostic Significance of Oncologists' Estimates and Scenarios for Survival Time in A Randomised Phase II Trial of Regorafenib in Advanced Gastric Cancer.” In Asia Pacific Journal of Clinical Oncology, 13:138–138. WILEY, 2017.Link to Item
-
Khasraw, M., M. S. Hofman, L. Chantrill, N. Pavlakis, V. Gebski, A. J. Gill, B. Markman, et al. “AGITG NABNEC: A randomised phase II study of nab-paclitaxel in combination with carboplatin as first line treatment of gastrointestinal neuroendocrine carcinomas.” In Annals of Oncology, Vol. 28. OXFORD UNIV PRESS, 2017.Link to Item
-
Vasista, A., A. Martin, N. Pavlakis, K. Sjoquist, S. Snow, D. Jonker, Y. J. Chua, et al. “Accuracy and prognostic significance of oncologists' estimates and scenarios for survival time in a randomised Phase 2 trial of regorafenib in advanced gastric cancer.” In Annals of Oncology, Vol. 28. OXFORD UNIV PRESS, 2017.Link to Item
-
Dass, P Hari, A. Pearson, H. Wheeler, and M. Khasraw. “Evaluating the Causes of Screen Failures in a Medical Oncology Clinical Trial Unit.” In Asia Pacific Journal of Clinical Oncology, 13:43–43. WILEY, 2017.Link to Item
-
Murphy, C., V. Mukaro, R. Tobler, R. Asher, E. Gibbs, L. West, B. Giuffre, S. Baron-Hay, and M. Khasraw. “Predicting Pathological Response: Accuracy of Magnetic Resonance Imaging Post Neoadjuvant Therapy for Breast Cancer in the Neonab Trial.” In Asia Pacific Journal of Clinical Oncology, 13:69–69. WILEY, 2017.Link to Item
-
Vasista, A., A. Martin, N. Pavlakis, K. Sjoquist, S. Snow, D. Jonker, Y. J. Chua, et al. “Accuracy and Prognostic Significance of Oncologists' Estimates and Scenarios for Survival Time in a Randomized Phase 2 Trial of Regorafenib in Advanced Gastric Cancer.” In Asia Pacific Journal of Clinical Oncology, 13:47–48. WILEY, 2017.Link to Item
-
McDonald, Kerrie Leanne, Wendy Ha, Hatice Sevim, Kazuko Matsuda, and Mustafa Khasraw. “Effect of treating glioblastoma with a cytokine inhibitor, ibudilast, in combination with temozolomide on survival in a patient-derived xenograft model.” In Journal of Clinical Oncology, 35:2062–2062. American Society of Clinical Oncology (ASCO), 2017. https://doi.org/10.1200/jco.2017.35.15_suppl.2062.Full Text
-
McDonald, K. L., W. Ha, and M. Khasraw. “TREATMENT OF RECURRENT GLIOBLASTOMA WITH THE CYTOKINE INHIBITOR, IBUDILAST IN COMBINATION WITH TEMOZOLOMIDE.” In Neuro Oncology, 19:27–27. OXFORD UNIV PRESS INC, 2017.Link to Item
-
Raymond, Eric, Matthew Kulke, Shukui Qin, Michael Schenker, Antonio Cubillo, Wenhui Lou, Jiri Tomasek, et al. “The Efficacy and Safety of Sunitinib in Patients With Advanced Well-differentiated Pancreatic Neuroendocrine Tumors.” In Pancreas, 46:435–435. LIPPINCOTT WILLIAMS & WILKINS, 2017.Link to Item
-
Raymond, Eric, Matthew H. Kulke, Shukui Qin, Michael Schenker, Antonio Cubillo, Wenhui Lou, Jiri Tomasek, et al. “The efficacy and safety of sunitinib in patients with advanced well-differentiated pancreatic neuroendocrine tumors.” In Journal of Clinical Oncology, 35:380–380. American Society of Clinical Oncology (ASCO), 2017. https://doi.org/10.1200/jco.2017.35.4_suppl.380.Full Text
-
Heimberger, Amy, Sarah Garber, Yuuri Hashimoto, Shiao-Pei Weathers, Joanne Xiu, Zoran Gatalica, Roel Verhaak, et al. “IMMUNE CHECKPOINT BLOCKADE AS A POTENTIAL THERAPEUTIC TARGET: SURVEYING CNS MALIGNANCIES.” In Neuro Oncology, 18:41–41. OXFORD UNIV PRESS INC, 2016.Link to Item
-
Holloway, K., M. A. Sajjad, M. Mohcbbi, M. Kotowicz, P. Livingston, M. Khasraw, S. Hakkennes, et al. “THE AGEING, CHRONIC DISEASE AND INJURY STUDY: EPIDEMIOLOGY OF HIP FRACTURES ACROSS WESTERN VICTORIA, AUSTRALIA.” In Osteoporosis International, 27:S732–33. SPRINGER LONDON LTD, 2016.Link to Item
-
McDonald, Kerrie, Swapna Joshi, and Mustafa Khasraw. “A COMBINATION OF PALBOCICLIB AND RADIOTHERAPY IMPROVES SURVIVAL IN GLIOBLASTOMA.” In Neuro Oncology, 18:63–63. OXFORD UNIV PRESS INC, 2016.Link to Item
-
McDonald, Kerrie, Wendy Ha, Hatice Sevim Nalkiran, and Mustafa Khasraw. “REPURPOSING IBUDILAST IN COMBINATION WITH TEMOZOLOMIDE FOR GLIOBLASTOMA.” In Neuro Oncology, 18:63–63. OXFORD UNIV PRESS INC, 2016.Link to Item
-
Wann, Alysson, Patrick Tully, Liz Barnes, Zarnie Lwin, Lindy Jeffree, Kate Drummond, Hui Gan, and Mustafa Khasraw. “OUTCOMES OF SECOND SURGERY FOR RECURRENT GLIOBLASTOMA MULTIFORME: A RETROSPECTIVE CASE CONTROL STUDY.” In Neuro Oncology, 18:192–192. OXFORD UNIV PRESS INC, 2016.Link to Item
-
Weller, M., G. Vlahovic, M. Khasraw, A. A. Brandes, R. Zwirtes, K. Tatsuoka, A. F. Carpentier, D. A. Reardon, and M. Bent. “A randomized phase 2, single-blind study of temozolomide (TMZ) and radiotherapy (RT) combined with nivolumab or placebo (PBO) in newly diagnosed adult patients (pts) with tumor O6-methylguanine DNA methyltransferase (MGMT)-methylated glioblastoma (GBM)—CheckMate-548.” In Annals of Oncology, 27:vi113, 2016. https://doi.org/10.1093/annonc/mdw367.34.Full Text
-
Khasraw, M., C. Murphy, V. Mukaro, L. West, K. White, C. Brandt, S. E. Baron-Hay, et al. “TAILORED NEOADJUVANT EPIRUBICIN AND CYCLOPHOSPHAMIDE (EC) AND NANOPARTICLE ALBUMIN- BOUND PACLITAXEL (NAB-P) IN BREAST CANCER.” In Asia Pacific Journal of Clinical Oncology, 12:44–44. WILEY-BLACKWELL, 2016.Link to Item
-
Khasraw, Mustafa, Violet Rudo Mukaro, Linda West, Karen White, Elisabeth Rippy, Conrad Brandt, Robert Tobler, et al. “Tailored neoadjuvant epirubicin and cyclophosphamide (EC) and nanoparticle albumin-bound paclitaxel (nab-P) in breast cancer.” In Journal of Clinical Oncology, 34:e12515–e12515. American Society of Clinical Oncology (ASCO), 2016. https://doi.org/10.1200/jco.2016.34.15_suppl.e12515.Full Text
-
Chan, David, Dale Bailey, Geoff Schembri, Elizabeth Bernard, Edward Hsiao, Tristan Barnes, Connie Diakos, et al. “Dual 18F-fluorodeoxyglucose/68Gallium DOTATATE (FDG/DOTA) PET grading and histological grade in neuroendocrine tumours (NET).” In Journal of Nuclear Medicine, Vol. 57. SOC NUCLEAR MEDICINE INC, 2016.Link to Item
-
Chan, D., D. Bailey, G. Schembri, E. Bernard, E. Hsiao, T. Barnes, C. Diakos, et al. “Dual 18F-Fluorodeoxyglucose/68Gallium DOTATATE (FDG/DOTA) PET Predicts Overall Survival in Neuroendocrine Tumours (NET).” In Neuroendocrinology, 103:55–55. KARGER, 2016.Link to Item
-
McDonald, Kerrie L., Mustafa Khasraw, Toni Rose Jue, Swapna Joshi, and Julia Yin. “Abstract A12: Genomically unstable glioblastoma are sensitive to Parp inhibition.” In Cancer Research, 75:A12–A12. American Association for Cancer Research (AACR), 2015. https://doi.org/10.1158/1538-7445.brain15-a12.Full Text
-
Chan, David L., John Leyden, Michael Michael, Timothy J. Price, Stephen Clarke, Nick Pavlakis, and Mustafa Khasraw. “SYMPTOM BURDEN OF AUSTRALIA AND NEW ZEALAND (ANZ) PATIENTS WITH NEUROENDOCRINE TUMOURS (NET).” In Asia Pacific Journal of Clinical Oncology, 11:168–168. WILEY-BLACKWELL, 2015.Link to Item
-
Chan, David L., John Leyden, Timothy J. Price, Michael Michael, Stephen Clarke, Connie Diakos, Mustafa Khasraw, et al. “EXPERIENCE OF AUSTRALIA AND NEW ZEALAND (ANZ) PATIENTS WITH NEUROENDOCRINE TUMOURS (NET) TREATED AT A NET SPECIALIST CENTRE: RESULTS OF A NATIONAL SURVEY AND THE ROYAL NORTH SHORE EXPERIENCE.” In Asia Pacific Journal of Clinical Oncology, 11:169–169. WILEY-BLACKWELL, 2015.Link to Item
-
Leyden, John, Nick Pavlakis, David Chan, Michael Michael, Stephen Clarke, Mustafa Khasraw, and Timothy Price. “NEUROENDOCRINE TUMOR (NET) OCEANIA PATIENT EXPERIENCE: RESULTS FROM THE FIRST GLOBAL NET PATIENT SURVEY - A COLLABORATION BETWEEN THE INTERNATIONAL NEUROENDOCRINE CANCER ALLIANCE (INCA) AND NOVARTIS.” In Asia Pacific Journal of Clinical Oncology, 11:86–86. WILEY-BLACKWELL, 2015.Link to Item
-
Segelov, E., S. Thavaneswaran, P. Waring, J. Desai, K. Mann, E. Elez, L. Chantrill, et al. “32LBA The AGITG ICECREAM Study: The Irinotecan Cetuximab Evaluation and Cetuximab Response Evaluation Amongst Patients with a G13D Mutation – analysis of outcomes in patients with refractory metastatic colorectal cancer harbouring the KRAS G13D mutation.” In European Journal of Cancer, 51:S726–S726. Elsevier BV, 2015. https://doi.org/10.1016/s0959-8049(15)30078-2.Full Text
-
Khasraw, Mustafa, Violet Rudo Mukaro, Linda West, Conrad Brandt, Anne Maree Woollett, Michelle Edwards, Robert Spokes, et al. “Tailored neoadjuvant epirubicin and cyclophosphamide (EC) and nanoparticle albumin bound (nab)-paclitaxel for newly diagnosed breast cancer (BC).” In Journal of Clinical Oncology, Vol. 33. AMER SOC CLINICAL ONCOLOGY, 2015.Link to Item
-
Ashley, David M., Andrea Muscat, Julia Yin, Elizabeth Algar, Kate Drummond, Mustafa Khasraw, Kathryn Maree Field, Nicholas Wong, Mark Rosenthal, and Kerrie Leanne McDonald. “Mutational analysis of matched initial and recurrent TP53 WT primary GBM.” In Journal of Clinical Oncology, 33:2043–2043. American Society of Clinical Oncology (ASCO), 2015. https://doi.org/10.1200/jco.2015.33.15_suppl.2043.Full Text
-
McDonald, Kerrie Leanne, Mustafa Khasraw, and David M. Ashley. “Identification of glioblastoma patients who stand to benefit from PARP inhibitor therapy.” In Journal of Clinical Oncology, 33:2071–2071. American Society of Clinical Oncology (ASCO), 2015. https://doi.org/10.1200/jco.2015.33.15_suppl.2071.Full Text
-
Wong, Shu Fen, Richard Norman, Trisha L. Dunning, David M. Ashley, Mustafa Khasraw, and Paula K. Lorgelly. “A discrete choice experiment to examine the preferences of patients with cancer and their willingness to pay for different types of health care appointments.” In Journal of Clinical Oncology, 33:6527–6527. American Society of Clinical Oncology (ASCO), 2015. https://doi.org/10.1200/jco.2015.33.15_suppl.6527.Full Text
-
McDonald, Kerrie, Kyoko Nozue-Okada, and Mustafa Khasraw. “Abstract 3777: Combining VELIPARIB (ABT-888) with temozolomide shows strong synergy when treating temozolomide-resistant and recurrent GBM cell lines.” In Cancer Research, 74:3777–3777. American Association for Cancer Research (AACR), 2014. https://doi.org/10.1158/1538-7445.am2014-3777.Full Text
-
Khasraw, Mustafa, Linda West, Wei Duan, Violet Mukaro, Sandra Harvey, Robert Spokes, Conrad Brandt, et al. “Tailored neoadjuvant epirubicin and cyclophosphamide and nanoparticle albumin bound (nab)-paclitaxel for newly diagnosed breast cancer.” In Journal of Clinical Oncology, 32:TPS1135–TPS1135. American Society of Clinical Oncology (ASCO), 2014. https://doi.org/10.1200/jco.2014.32.15_suppl.tps1135.Full Text
-
Khasraw, Mustafa, Malaka Ameratunga, Andrew B. Lassman, David M. Ashley, Helen Wheeler, and Nick Pavlakis. “A meta-analysis of antiangiogenic therapy for glioblastoma (GBM).” In Journal of Clinical Oncology, 32:2047–2047. American Society of Clinical Oncology (ASCO), 2014. https://doi.org/10.1200/jco.2014.32.15_suppl.2047.Full Text
-
Khasraw, Mustafa, Sally Anne McCowatt, Marc E. Buyse, Zoltan Kerstes, Michael Back, Ganessan Kichenadasse, and Helen Wheeler. “Radiotherapy (RT), temozolomide (TMZ), procarbazine (PCB), and the integrin inhibitor cilengitide in patients (pts) with glioblastoma (GBM) without methylation of the MGMT gene promoter (ExCentric): Results of an Australian phase II clinical trial.” In Journal of Clinical Oncology, 32:2050–2050. American Society of Clinical Oncology (ASCO), 2014. https://doi.org/10.1200/jco.2014.32.15_suppl.2050.Full Text
-
Waring, Paul Michael, Jayesh Desai, Zbigniew Barney Rudzki, Kate Wilson, Val Gebski, Louise M. Nott, Christos Stelios Karapetis, et al. “Prospective evaluation of KRAS, NRAS, BRAF, and PI3KCA mutation screening for patient enrolment in AGITG ICECREAM (Irinotecan Cetuximab Evaluation and the Cetuximab Response Evaluation among Patients with G13D Mutation) trial in metastatic colorectal cancer (mCRC).” In Journal of Clinical Oncology, 32:e14536–e14536. American Society of Clinical Oncology (ASCO), 2014. https://doi.org/10.1200/jco.2014.32.15_suppl.e14536.Full Text
-
Mendis, S., C. Murphy, S. Bowles, and M. Khasraw. “A RETROSPECTIVE STUDY OF WOMEN WITH LATE PRESENTATIONS OF BREAST CANCER.” In Asia Pacific Journal of Clinical Oncology, 10:63–63. WILEY-BLACKWELL, 2014.Link to Item
-
Ameratunga, Malaka, Adam Broad, Nick Pavlakis, Val Gebski, and Mustafa Khasraw. “EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITORS IN ADVANCED SQUAMOUS CELL CARCINOMA OF THE LUNG.” In Journal of Thoracic Oncology, 8:S1189–S1189. LIPPINCOTT WILLIAMS & WILKINS, 2013.Link to Item
-
Khasraw, Mustafa, Violet R. Mukaro, Michael Berk, Greg Wheeler, Madhu Singh, Chris Brown, Michael Francis, et al. “LITHIUM AS A NEUROPROTECTIVE AGENT IN PATIENTS UNDERGOING PROPHYLACTIC CRANIAL IRRADIATION (PCI) FOR SMALL CELL LUNG CANCER (SCLC): THE TULIP STUDY.” In Journal of Thoracic Oncology, 8:S932–S932. LIPPINCOTT WILLIAMS & WILKINS, 2013.Link to Item
-
Li, Bob T., Csilla Hasovits, Adrian Lee, Angela E. Li, Mustafa Khasraw, Gavin Marx, and Nick Pavlakis. “THE ADDITION OF ANTI-ANGIOGENIC TYROSINE KINASE INHIBITORS TO CHEMOTHERAPY FOR ADVANCED NON-SMALL CELL LUNG CANCER: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMISED CONTROLLED TRIALS.” In Journal of Thoracic Oncology, 8:S608–S608. LIPPINCOTT WILLIAMS & WILKINS, 2013.Link to Item
-
Khasraw, M., L. West, G. Mitchell, K. White, I. Olesen, K. Prince, C. Brandt, et al. “TAILORED NEOADJUVANT EPIRUBICIN AND CYCLOPHOSPHAMIDE AND NANOPARTICLE ALBUMIN BOUND (NAB) PACLITAXEL FOR NEWLY DIAGNOSED BREAST CANCER.” In Asia Pacific Journal of Clinical Oncology, 9:56–57. WILEY-BLACKWELL, 2013.Link to Item
-
Cosman, Rasha, Chris Brown, Kevin DeBraganca, and Mustafa Khasraw. “Patterns of care study of adult medulloblastoma.” In Journal of Clinical Oncology, Vol. 31. AMER SOC CLINICAL ONCOLOGY, 2013.Link to Item
-
Segelov, Eva, Kate Wilson, Val Gebski, Paul Michael Waring, Josep Tabernero, Harpreet Wasan, Fortunato Ciardiello, et al. “ICE CREAM: Irinotecan cetuximab evaluation and the cetuximab response evaluation among patients with G13D mutation.” In Journal of Clinical Oncology, Vol. 31. AMER SOC CLINICAL ONCOLOGY, 2013.Link to Item
-
Khasraw, Mustafa, Chris Brown, David M. Ashley, and Mark A. Rosenthal. “A METANALYSIS OF ALTERNATIVE SCHEDULE OF TEMOZOLOMIDE (TMZ) IN RECURRENT MALIGNANT GLIOMA (MG).” In Neuro Oncology, 13:50–50. OXFORD UNIV PRESS INC, 2011.Link to Item
-
Jhaveri, K. L., S. Patil, M. Khasraw, J. Bhatia, Z. K. Stadler, N. D. Kauff, C. Hudis, K. Offit, and M. E. Robson. “Risk of breast cancer (BC) after BRCA-mutation associated ovarian cancer (BRCA-OC): Memorial Sloan-Kettering Cancer Center (MSKCC) experience.” In Journal of Clinical Oncology, 29:1518–1518. American Society of Clinical Oncology (ASCO), 2011. https://doi.org/10.1200/jco.2011.29.15_suppl.1518.Full Text
-
Khasraw, M., S. A. McCowatt, Z. Kerestes, M. E. Buyse, M. Back, and H. Wheeler. “Radiotherapy (RT), temozolomide (TMZ), procarbazine (PCB), and the integrin inhibitor cilengitide in patients with glioblastoma (GBM) without methylation of the MGMT gene promoter (ExCentric).” In Journal of Clinical Oncology, 29:TPS133–TPS133. American Society of Clinical Oncology (ASCO), 2011. https://doi.org/10.1200/jco.2011.29.15_suppl.tps133.Full Text
-
Saaed, A. M., A. K. Sheikha, S. S. Mohammed, H. A. M. Ameen, S. Y. Sheet, and M. Khasraw. “A survey of suspected familial breast cancer in Iraqi Kurdish women.” In Journal of Clinical Oncology, 29:1602–1602. American Society of Clinical Oncology (ASCO), 2011. https://doi.org/10.1200/jco.2011.29.15_suppl.1602.Full Text
-
Sheet, S. Y., A. K. Sheikha, A. M. Saaed, H. A. M. Ameen, S. S. Mohammed, and M. Khasraw. “Presenting features of colorectal cancerin the Sulaimaniya province of Iraqi Kurdistan.” In Journal of Clinical Oncology, 29:e14148–e14148. American Society of Clinical Oncology (ASCO), 2011. https://doi.org/10.1200/jco.2011.29.15_suppl.e14148.Full Text
-
Khasraw, Mustafa, Lauren E. Abrey, Andrew B. Lassman, Adilia Hormigo, Craig Nolan, Igor T. Gavrilovic, Ingo K. Mellinghoff, Anne S. Reiner, Lisa DeAngelis, and Antonio M. Omuro. “PHASE II TRIAL OF CONTINUOUS LOW-DOSE TEMOZOLOMIDE (TMZ) FOR PATIENTS WITH RECURRENT MALIGNANT GLIOMA (MG) WITH AND WITHOUT PRIOR EXPOSURE TO BEVACIZUMAB (REV).” In Neuro Oncology, 12:72–72. OXFORD UNIV PRESS INC, 2010.Link to Item
-
Khasraw, Mustafa, Thomas Kaley, Katherine Panageas, Anne Reiner, Samuel Goldlust, and Vivian Tabar. “SURVIVAL AND TREATMENT OF CRANIAL METASTASES (CMS) FROM NEUROENDOCRINE TUMORS (NETS) AT MEMORIAL SLOAN-KETTERING CANCER CENTER (MSKCC).” In Neuro Oncology, 12:46–46. OXFORD UNIV PRESS INC, 2010.Link to Item
-
Khasraw, M., L. E. Abrey, A. B. Lassman, A. Hormigo, C. Nolan, I. T. Gavrilovic, I. K. Mellinghoff, A. S. Reiner, L. M. DeAngelis, and A. M. Omuro. “Phase II trial of continuous low-dose temozolomide (TMZ) for recurrent malignant glioma (MG) with and without prior exposure to bevacizumab (BEV).” In Journal of Clinical Oncology, 28:2065–2065. American Society of Clinical Oncology (ASCO), 2010. https://doi.org/10.1200/jco.2010.28.15_suppl.2065.Full Text
-
Khasraw, Mustafa, Samuel A. Goldlust, Andrew B. Lassman, and Lisa M. DeAngelis. “Retrospective Review of Symptomatic Intracranial Hemorrhage (ICH) in Cancer Patients Treated with Bevacizumab; the Memorial Sloan-Kettering (MSK) Experience.” In Neurology, 74:A594–A594. LIPPINCOTT WILLIAMS & WILKINS, 2010.Link to Item
-
Khasraw, Mustafa, Nick Pavlakis, and Helen Wheeler. “A RETROSPECTIVE SINGLE INSTITUTIONAL ANALYSIS OF CILENGITIDE (CGT) AND CHEMOTHERAPY FOR HEAVILY PRETREATED RECURRENT GLIOBLASTOMA MULTIFORME (GBM).” In Neuro Oncology, 11:952–952. OXFORD UNIV PRESS INC, 2009.Link to Item
-
Khasraw, Mustafa, Nick Pavlakis, and Helen Wheeler. “ABSENCE OF EVIDENCE IS NO EVIDENCE OF ABSENCE.” In Neuro Oncology, 10:816–816. OXFORD UNIV PRESS INC, 2008.Link to Item
-
Khasraw, M., and G. Marx. “Chemotherapy in the elderly.” In Cancer Forum, 32:8–11, 2008.
-
Ney, Douglas, Lisa Deangelis, Craig Nolan, Igor Gavrilovic, Adilia Hormigo, Andrew Lassman, and Lauren Abrey. “PHASE II TRIAL OF CONTINUOUS LOW-DOSE TEMOZOLOMIDE FOR PATIENTS WITH RECURRENT MALIGNANT GLIOMA.” In Neuro Oncology, 10:831–831, 2008.Link to Item
-
-
- Teaching & Mentoring
-
Recent Courses
-
Advising & Mentoring
Available to mentor:
- Faculty
- Fellow
- Masters
- PhD
- Post-Doc
- Professional
- Resident
- Undergraduate
- Scholarly, Clinical, & Service Activities
-
Academic & Administrative Activities
-
Academic & Administrative Activities
Last 5 years only2022 NIH Oncology Fellowship Study Section Reviewer
2022 Unmet Medical Need, Italian Regional Foundation for Biomedical Research Reviewer
2022-Ongoing Associate Editor, Neurooncology Advances (NOA)
2021-Ongoing Co-chair of the joint ASCO-SNO Clinical Trials Conference planned Oct 20212021- Reviewer for DESP - Cellule Mesures, Indicateurs, Bibliométrie. French Gov Granting Agency
2021- Member of NRG site-specific eligibility criteria development committee for CNS cancer
2020- Clinical Trials TRACK lead, Society of Neurooncology (SNO)
2020- Health Research Council of New Zealand Grant Reviewer
2019- ongoing Co-chair, Clinical Trials Course and Workshop, Society of Neurooncology
2019 Chair, Clinical Trials Reform Think Tank, Society of Neurooncology
2019- ongoing member of the editorial board; Neurooncology
2019- Associate editor of the Asia Pacific JCO (Journal of Clinical Oncology)
2018-2019 Innovative Trial Design Reference Group Lead for the Australian Clinical Trials Alliance (ACTA)
2018-2019 joint panel of the American Society of Clinical Oncology (ASCO), the Congress of Neurological Surgeons and SNO for Guidelines for Brain Metastases
2018-2020 Co-chair of the international outreach committee of the Society of Neurooncology(SNO)
2016-2018 Australian Government NHMRC Grants, Review Panel member
2016-2018 Australian Medicare Benefit Scheme, Member of the Oncology Clinical Committee.
2016 Chair of the scientific program of the Asian Society of Neurooncology meeting
-
Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.